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ABSTRACT 
 
 Schizophrenia is a neurodevelopmental disorder affecting 1% of the general 
population. Dysfunction of the prefrontal cortex (PFC) is associated with the 
etiology of schizophrenia. Moreover, a substantial deficit of GAD1 mRNA in 
schizophrenic PFC has been reported by different groups. However, the 
underlying molecular mechanisms are still unclear. Interestingly, epigenetic 
factors such as histone modifications and DNA methylation could be involved in 
the pathogenesis of schizophrenia during the maturation of the PFC. In my work, I 
identified potential epigenetic changes in schizophrenic PFC and developmental 
changes of epigenetic marks in normal human PFC. Furthermore, mouse and 
neuronal precursor cell models were used to confirm and investigate the 
molecular mechanisms of the epigenetic changes in human PFC.  
My initial work examined whether chromatin immunoprecipitation can be 
applied to human postmortem brain. I used micrococcal nuclease 
(MNase)-digested chromatin instead of cross-linked and sonicated chromatin for 
further immunoprecipitation with specific anti-methyl histone antibodies. 
Surprisingly, the integrity of mono-nucleosomes was still maintained at least 30 
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hrs after death. Moreover, differences of histone methylation at different genomic 
loci were detectable and were preserved within a wide range of autolysis times 
and tissue pH values. Interestingly, MNase-treated chromatin is more efficient for 
subsequent immunoprecipitation than crosslinked and sonicated chromatin.  
During the second part of my dissertation work, I profiled histone methylation 
at GABAergic gene loci during human prefrontal development. Moreover, a 
microarray analysis was used to screen which histone methyltransferase (HMT) 
could be involved in histone methylation during human prefrontal development. 
Mixed-lineage leukemia 1 (MLL1), an HMT for methylation at histone H3 lysine 4 
(H3K4), appears to be the best candidate after interpreting microarray results. 
Indeed, decreased methylation of histone H3 lysine 4 at a subset of GABAergic 
gene loci occurred in Mll1 mutant mice. Interestingly, clozapine, but not 
haloperidol, increased levels of trimethyl H3K4 (H3K4me3) and Mll1 occupancy at 
the Gad1 promoter. I profiled histone methylation and gene expression for GAD1 
in schizophrenics and their matched controls. Interestingly, there are deficits of 
GAD1 mRNA levels and GAD1 H3K4me3 in female schizophrenics. Furthermore, 
I was also interested in whether the changes of GAD1 chromatin structure could 
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contribute to cortical pathology in schizophrenics with GAD1 SNPs. Remarkably, 
homozygous risk alleles for schizophrenia at the 5’ end of the GAD1 gene are 
associated with a deficit of GAD1 mRNA levels together with decreased GAD1 
H3K4me3 and increased GAD1 H3K27me3 in schizophrenics. 
Finally, I shifted focus on whether DNA methylation at the GAD1 promoter 
could contribute to a deficit of GAD1 mRNA in schizophrenia. However, no 
reproducible techniques are available for extracting genomic DNA specifically 
from GABAergic neurons in human brain. Therefore, I used an alternative 
approach that is based on immunoprecipitation of mononucleosomes with 
anti-methyl-histone antibodies differentiating between sites of active and silenced 
gene expression. The methylation frequencies of CpG dinucleotides at the GAD1 
proximal promoter and intron 2 were determined from two chromatin fractions 
(H3K4me3 and H3K27me3) separately. Consistently, the proximal promoter 
region of GAD1 is more resistant to methylation in comparison to intron 2 of GAD1 
in either open or repressive chromatin fractions. Interestingly, overall higher levels 
of DNA methylation were seen in repressive chromatin than in open chromatin. 
Surprisingly, schizophrenic subjects showed a significant decrease of DNA 
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methylation at the GAD1 proximal promoter from repressive chromatin. 
 Taken together, my work has advanced our knowledge of epigenetic 
mechanisms in human prefrontal development and the potential link to the 
etiology of schizophrenia. It could eventually provide a new approach for the 
treatment of schizophrenia, especially in the regulation of methylation at histone 
H3 lysine 4.  
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CHAPTER I: INTRODUCTION 
Schizophrenia 
 Schizophrenia is a mental disorder which is characterized by positive and 
negative symptoms (Lecrubier et al., 2007). Positive symptoms are abnormal 
perceptions and thoughts, which include auditory hallucinations, delusions and 
disorganized thinking. In contrast, negative symptoms refer to loss or decrease of 
normal functions. For instance, patients could experience apathy, blunted affect, 
impaired attention and poor speech. Schizophrenia was originally described by 
Emile Kraepelin in 1887 (Engstrom and Weber, 2005) as dementia praecox or 
“dementia as early onset” and was given its current name by Eugen Bleuler in 
1911 (Stotz-Ingenlath, 2000). However, this disease is widely believed to have 
accompanied humankind’s whole history. Importantly, Kraepelin’s and Bleuler’s 
pioneering works and observations have contributed to the current criteria for 
diagnosing schizophrenia (Andreasen and Carpenter, 1993). These criteria are 
specified in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV; 
(Andreasen and Carpenter, 1993)), which is generally used by mental health 
professionals as a reliable and consistent tool for diagnosing mental disorders. 
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Based on the DSM-IV, schizophrenia is classified into 5 different subtypes: 
disorganized, catatonic, paranoid, undifferentiated and residual types. Each 
subtype consists of a different combination of positive and/or negative symptoms 
(Jablensky, 2006).  
 Age at onset of schizophrenia varies widely. Onset age also differs by 
gender.  Men begin to develop schizophrenia from their late teens to early 20s, 
whereas women start to experience schizophrenia from their late 20s to early 30s 
(Hafner et al., 1998; Lieberman et al., 2001). Regardless of gender or culture, 
schizophrenia has a prevalence rate of 1%. The prevalence is lower in children, 
with onset by age 12, occurring only about 1 in 40,000. Importantly, 
childhood-onset schizophrenia is biologically and clinically continuous with 
adult-onset schizophrenia (Nicolson and Rapoport, 1999). Moreover, older adults 
infrequently develop schizophrenia, i.e., late-onset schizophrenia (onset after age 
40) and very-late-onset schizophrenia-like psychosis (onset after age 60) are rare 
(Howard et al., 2000). These results suggest that the pathogenesis of 
schizophrenia involves developmental and degenerative processes.  
 The causes of schizophrenia are still unclear. No single cause can explain 
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this disorder, although genetic factors could be involved. For example, individuals 
with schizophrenic parents or siblings are almost 10 times more likely to develop 
schizophrenia. Indeed, at least 17 schizophrenia susceptibility genes have been 
identified (Straub and Weinberger, 2006). 
 However, genetic factors don’t tell the whole story. For instance, 
monozygotic twins have only a 50% concordance rate for schizophrenia, and 
dizygotic twins have a 15% concordance rate (Lichtenstein et al., 2006). These 
facts indicate that genetic factors are important, but are not the only key players in 
the pathogenesis of schizophrenia. Therefore, the development of this disease 
could be influenced by environmental factors during the development and 
maturation of the brain. 
 The development of schizophrenia has been associated with several 
environmental factors: malnutrition in utero (Kroll, 2007), birth trauma (Cannon et 
al., 2002), viral infection in pregnancy (Fatemi et al., 2008), living in urban areas 
(Fatemi et al., 2008), or even birth in winter or spring time (Davies et al., 2003). 
Another favored theory is that this disorder could be influenced by abnormalities 
in brain structure (Lawrie et al., 2008), neuronal circuitry, or neurotransmitters 
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(Benes, 2000). As to brain structure, schizophrenics’ brains have been shown to 
contain enlarged ventricles (Morgan et al., 2007) or more markedly asymmetric 
hemispheres (Mintz et al., 1982). Moreover, schizophrenic prefrontal cortex has 
shown dysfunctional activity (Johnson et al., 2006). Interestingly, this disease 
might be influenced by an imbalance of neurotransmitters such as dopamine, 
glutamate, serotonin and gamma-aminobutyric acid (GABA). These 
neurotransmitters could be involved in the connectivity of neuronal circuits which 
are related to the symptoms of schizophrenia (Carlsson, 2006).  
 The major treatment for schizophrenia includes antipsychotic medications. 
The rationale for using these drugs is to adjust the imbalance of neurotransmitters 
in schizophrenia (Stone and Pilowsky, 2007). Currently used antipsychotics fall 
into two categories: typical antipsychotics (or neuroleptics) and atypical 
antipsychotics. Typical antipsychotics, including haloperidol (Haldol), 
chlorpromazine (Thorazine), and fluphenazine (Prolixin), have been used to treat 
schizophrenic patients since the mid-1950s. Neuroleptics block dopamine D2-like 
receptors and reduce positive symptoms, but have extrapyramidal side effects 
such as reducing the ability to initiate movement and causing the patient to remain 
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motionless (Bishnoi et al., 2007).  
 Atypical antipsychotics, which include quetiapine (Seroquel), risperidone 
(Risperdal), olanzapine (Zyprexa) and clozapine (Clozaril), have been prescribed 
to schizophrenic patients since the 1990s (Crilly, 2007). These drugs block a 
variety of neurotransmitter receptors, thus decreasing positive and negative 
symptoms. Unfortunately, clozapine has a very severe side effect, 
agranulocytosis (a severe decrease of blood granulocytes). When medications 
are discontinued in patients with schizophrenia after 1 year, they have a high 
relapse rate (69%) (Ayuso-Gutierrez and del Rio Vega, 1997). Moreover, 
schizophrenic patients are prone to be depressed and have an increased risk of 
committing suicide. In fact, around 10% of schizophrenic patients die by 
committing suicide (Pompili et al., 2007). Therefore, antidepressants are also 
administered to patients with schizophrenia.  
 Research on schizophrenia has been greatly facilitated by use of animal 
models. Mice displaying schizophrenia-associated phenotypes have been 
generated by manipulating schizophrenia susceptibility genes, including Disc1 
(Hikida et al., 2007; Li et al., 2007; Pletnikov et al., 2008), Reelin (Brigman et al., 
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2006; Pillai and Mahadik, 2008),  Stop (Brenner et al., 2007; Powell et al., 2007), 
TA1 (Wolinsky et al., 2007), Synapsin II (Dyck et al., 2007), PLC-beta 1 (Koh et al., 
2008), calcineurin (Miyakawa et al., 2003), Fgfr1 (Klejbor et al., 2006), neuregulin 
1 (Karl et al., 2007), Nurr1 (Rojas et al., 2007), and GluR1 (Wiedholz et al., 2007). 
These genetically engineered mice have proven to be useful tools for studying the 
treatment and neuropathology of schizophrenia.  
 Other rodent models used to mimic schizophrenia symptoms have been 
generated either by drug treatment or by tissue lesion. For instance, rodents 
treated with drugs targeting neurotransmitter receptors or DNA methylation exhibit 
symptoms that bear similarities to aspects of schizophrenia. These drugs include 
amphetamine (dopamine-mimetic), phencyclidine (N-methyl D-aspartate [NMDA] 
antagonist), ketamine (NMDA antagonist), picrotoxin (GABA-A receptor 
antagonist)(Berretta and Benes, 2006), lysergic acid diethylamide (LSD, serotonin 
receptor agonist), and L-methionine (DNA methylation). An example of a model 
induced by tissue lesion is the rat with hippocampal-lesions (Chambers et al., 
1996). So far, no animal model generated by any of these methods shows the full 
spectrum of schizophrenia symptoms. 
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 Prefrontal cortex 
 The etiology of schizophrenia has been linked by several lines of evidence to 
alterations in the neural circuitry of the prefrontal cortex (PFC) (Mirnics et al., 2000; 
Hashimoto et al., 2008) and to disturbances in specific forms of memory 
associated with the PFC, particularly working memory (WM) (Lewis and 
Lieberman, 2000). The PFC is located at the most anterior area of the frontal lobe, 
which along with the parietal, temporal and occipital lobes, forms the human 
neocortex. The key function of the PFC is involved in complex cognition by using 
WM to hold information for later processing through either enhanced spiking 
activity (Miller et al., 1996) or synaptic facilitation (Mongillo et al., 2008). 
In human, the PFC comprises 29% of the neocortex, whereas in macaques 
and cats the PFC occupies only 11.5 and 3.5% of the cortex, respectively (Fuster, 
2002). These differences in the PFC reflect an evolutionary expansion that is 
related to the evolution in cognitive function of these species. The PFC develops 
and matures relatively later than other areas of cortex as shown by the PFC’s late 
axon myelination, a marker of late neuronal development (Fuster, 2002). Even 
within the PFC, different areas develop in a different order. For instance, the 
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ventromedial PFC develops earlier than the lateral PFC (Fuster, 2002). This 
developmental difference has been associated in neuropsychological studies with 
lower functions (emotional and instinctual behaviors) in the ventromedial PFC and 
with higher executive functions (temporal organization of actions in the domains of 
behavior, cognition and language) in the lateral PFC (Fuster, 2002).  
The human prefrontal cortex has several sub-regions: ventromedial, 
dorsomedial (BA 9), ventrolateral, dorsolateral (BA 46), rostral (BA10) and 
orbitofrontal (BA 11 & 12) areas (Blumberg et al., 1999; Frey and Petrides, 2000; 
Grimm et al., 2006). The functions of these sub-regions have been determined by 
lesion and imaging approaches. The ventromedial PFC is involved during 
decision-making in choosing between rewarding and punitive outcomes (Oya et 
al., 2005). The dorsomedial prefrontal cortex has been implicated in 
decision-making and planning (Manes et al., 2002). The ventral and dorsal lateral 
prefrontal cortices together contribute to working memory (Muller and Knight, 
2006), the rostral PFC is linked to prospective memory (Okuda et al., 2007), and 
the orbitofrontal PFC has been associated with encoding information and 
discrimination learning (Frey and Petrides, 2000; Chase et al., 2007).  
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 The PFC is connected by neural circuits to other areas of the neocortex and 
to subcortical regions, and deficits in these circuits have been associated with 
neuropsychiatric diseases. For example, the PFC receives afferent input from the 
mediodorsal thalamic nuclei and, to a lesser extent, from the anterior thalamic 
nuclei (Lewis and Lieberman, 2000). On the other hand, the PFC sends efferent 
output to basal ganglia and the midbrain (substantia nigra/ventral tegmental area 
[SN/VTA]) (Beckstead, 1979). Therefore, the PFC indirectly regulates the release 
of dopamine. The human PFC is divided into 6 layers with two major types of 
neurons: excitatory pyramidal neurons and inhibitory GABAergic neurons (Lewis 
and Lieberman, 2000). 
 
GABAergic neurons 
 GABA, an inhibitory neurotransmitter, is released by GABAergic neurons, 
which make up 25% of cortical neurons. The axons of GABAergic neurons project 
and act locally on pyramidal neurons, and their dendrites are smooth (Wonders 
and Anderson, 2006). GABAergic neurons mature in mice after birth. Different 
types of GABAergic neurons are regulated both before and after birth in distinct 
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temporal and spatial ways (Davila et al., 2005). Most cortical GABAergic neurons 
in rodents derive originally from the ganglionic eminence of the ventral forebrain 
(Wonders and Anderson, 2006), but, in the human neocortex, only 35% of 
GABAergic neurons originate in the ganglioinic eminence (Wonders and 
Anderson, 2006). The other 65% of human cortical GABAergic neurons are from 
the ventricular and subventricular zones of the dorsal forebrain (Letinic et al., 
2002). 
Regulation of GABAergic neurons is activity-dependent and reversible. For 
instance, GABAergic neuronal markers (GABA, GAD, tachykinin and GABAA 
receptors) decrease on the denervated side of the monkey visual cortex after 
monocular deprivation (Hendry and Jones, 1988; Benson et al., 1994; Hendry et 
al., 1994). Interestingly enough, GABAergic neurons also have excitatory effects 
during embryonic and neonatal stages due to the early expression of Na+-K+-2Cl- 
co-transporters (NKCCs) and delayed expression of the K+-Cl- co-transporter 
(KCC2) in immature neurons (Ben-Ari, 2002; Liu et al., 2006). Remarkably, 
GABAergic excitation promotes neuronal differentiation and morphological 
maturation (Tozuka et al., 2005; Cancedda et al., 2007). 
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GABAergic neurons can be subdivided by their morphology, 
electrophysiology, transcriptional factors or neurochemical components (Flames 
and Marin, 2005; Wonders and Anderson, 2006). One class of chemical 
components comprises calcium-binding proteins such as parvalbumin (PV), 
calretinin (CR) or calbindin (CB). Another class of chemical components consists 
of neuropeptides such as neuropeptide Y (NPY), somatostatin (SST), vasoactive 
intestinal peptide (VIP) or cholecystokinin (CCK). Based on their chemical 
components, GABAergic neurons are classified into 3 distinct populations: PV, 
SST/CB and CR/VIP. PV- or SST-positive GABAergic neurons originate in the 
medial ganglionic eminence, whereas, CR-positive GABAergic neurons are 
originally from the dorsal caudate ganglionic eminence in mice (Flames and Marin, 
2005; Wonders and Anderson, 2006).  
Classification of GABAergic neurons by electrophysiology is according to 
their different firing patterns, e.g., fast-spiking, burst-spiking, or regular-spiking 
(Flames and Marin, 2005). Another classification of GABAergic neurons depends 
on morphology, e.g., small basket, large basket, nest basket, axo-axonic 
(chandelier cell), ivy (Fuentealba et al., 2008), small bipolar and small multipolar 
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(Martinotti cell) cells. Fast-spiking GABAergic neurons contain PV and exist as 
chandelier cells. Burst-spiking GABAergic neurons express SST/CB and exist as 
Martinotti cells. Moreover, regular-spiking GABAergic neurons have CR/VIP and 
appear as small bipolar cells (Flames and Marin, 2005).  
GABAergic neurons contain the above neurochemical components in 
different relative abundance. For instance, half of GABAergic neurons contain PV, 
whereas only 30% are positive for SST/CB and 15% express CR/VIP (Wonders 
and Anderson, 2006). Moreover, different types of GABAergic neurons have 
different postsynaptic targets. PV-containing GABAergic neurons primarily 
innervate neuronal soma, initial segments of axons and proximal dendrites. 
CR/VIP-containing GABAergic neurons selectively innervate proximal dendrites. 
Furthermore, SST/CB-containing GABAergic neurons selectively innervate distal 
dendtrites, soma and proximal dendrites (Wonders and Anderson, 2006). This 
rich pattern of innervation begins in utero and it is not completed until late 
adolescence (Di Cristo, 2007). Therefore, the maturation and formation of 
GABAergic synapses is a prolonged process. GABAergic neurons have also 
recently been classified by the transcriptional factors they express, thus reflecting 
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recent advances in understanding the transcriptional regulation of specification 
and differentiation of GABAergic neurons (Wonders and Anderson, 2006).  
 GABA is synthesized from glutamate by the enzyme, glutamic acid 
decarboxylase 1 (GAD1 or GAD67), which is highly expressed in the brain. Unlike 
GAD1, GAD2 (GAD65), another isoform of GAD, is highly expressed in both brain 
and pancreas (Chessler and Lernmark, 2000). Interestingly, GAD25 and GAD44, 
two spliced forms of GAD1, appear predominantly in embryonic brains, whereas  
GAD1 and GAD2 dominate in adult brains (Varju et al., 2002). Moreover, 
Gad1-knockout mice show decreased GABA levels and severe cleft palate, 
resulting in death during the first morning after birth (Asada et al., 1997). However, 
Gad2-knockout mice display normal GABA levels although they are susceptible to 
seizures (Asada et al., 1996). GAD1 mRNA levels have been shown to be 
robustly decreased in postmortem schizophrenic prefrontal cortices (Akbarian and 
Huang, 2006). Furthermore, schizophrenia has been associated with single 
nucleotide polymorphisms (SNPs) at the promoter and 5’ end of the GAD1 gene 
(Lappalainen et al., 2004; Addington et al., 2005; Lundorf et al., 2005; Straub et al., 
2007b; Zhao et al., 2007; Du et al., 2008). These lines of evidence show the 
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importance of GAD1 in the pathogenesis of schizophrenia. 
 
Epigenetic factors in schizophrenia  
Hereditary information can be passed down through not only genetic factors 
but also epigenetic factors, which include post-translational, covalent 
modifications at the N-terminal tails of histone proteins and DNA methylation. 
Therefore, epigenetic modifications do not change the DNA sequence. Epigenetic 
mechanisms could contribute to a variety of cellular and molecular processes 
such as gene transcription, imprinting, chromosome X inactivation and 
heterochromatin formation (Peterson and Laniel, 2004; Hoffman and Hu, 2006). 
Histone modification. Chromatin consists of DNA and proteins that are 
packed into higher-level DNA structures, chromosomes. The basic unit of 
chromatin structure is the nucleosome, which consists of one histone octamer 
wrapped 1.75 times with 146-bp DNA (Peterson and Laniel, 2004). Histones not 
only pack chromosomal DNA to fit into the nucleus, but they also increase the 
accessibility of nucleosomal DNA and internucleosomal contacts by 
post-translational modifications at the N-terminal tails of histones themselves. The 
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latter mechanism reflects the status of gene activity, e.g., gene expression or 
repression (see below).  
Histone octamers contain histone H3-H4 tetramers flanked by H2A-H2B 
dimers. Histone H1 helps nucleosomes form higher-level chromatin structures by 
stabilizing already formed compact DNA fibers. Unstructured N-terminal tails of 
histones can be modified by methylation, acetylation, phosphorylation, 
ubiquitination, and sumoylation. Each type of modification reflects a distinct status 
of gene expression. For instance, acetylation and phosphorylation at specific 
residues are linked to gene activation, whereas methylation and ubiquitination are 
associated with either gene activation or repression, and sumoylation is linked to 
gene repression (Berger, 2007). Interestingly, different forms of methylated 
(mono-, di-, tri-) histones at lysine residues are involved in different states of gene 
activity, thus adding another layer of complexity to interpreting the epigenetic 
code.  
Histone methylation is stable relative to the reversibility and dynamics of 
histone acetylation and phosphorylation (Bui et al., 2006; Bui et al., 2007; 
Adegbola et al., 2008). Histones can be methylated at either lysine or arginine 
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residues. Interestingly, lysine residues can be mono-, di- or tri-methylated, but 
arginine residues can only be mono- or di-methylated (symmetrically or 
asymmetrically in the latter case) (Bannister et al., 2002). Histones are methylated 
by histone methyltransferases (HMTs) specific for histone lysine residues (HKMTs; 
(Rea et al., 2000) or histone arginine residues (HRMTs; (Wang et al., 2001).  
Histone methyltransferases for lysine residues (HKMTs) have been 
discovered. For example, HKMTs consist of the SET domain-containing protein 
family and Dot1/DOT1L proteins. The SET domain-containing protein family 
contains SET1, SET2, SUV39, EZH, SMYD, the PRDM family and others (Volkel 
and Angrand, 2007). In contrast to HKMTs, only one family of histone arginine 
methyltransferase (HRMT) has been found so far, the PRMT protein family 
(Zhang and Reinberg, 2001). Methylation at the histone tails can be removed by 
histone demethylases (HDMs). Similar to HMTs, HDMs are specific for histone 
lysine and arginine residues. For example, lysine-specific HDMs are LSD1 and 
the JmjC domain-containing protein family (Klose and Zhang, 2007), while an 
arginine-specific HDM is JMJD6 (Chang et al., 2007).  
The methylation of different lysines reflects the status of gene activity. For 
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instance, methylations at histone H3 lysine 4 (H3K4), lysine 36 (H3K36) and 
lysine79 (H3K79) are associated with gene activation (Volkel and Angrand, 2007). 
On the other hand, methylations at histone H3 lysine 9 (H3K9) and lysine 27 
(H3K27) and at histone H4 lysine 20 (H4K20) are linked to gene repression. 
Interestingly enough, methylated lysines can be recognized by certain modulator 
protein domains, e.g., the chromodomain, WD40 repeat, Tutor domain, MBT 
domain and PHD finger domains (Volkel and Angrand, 2007). The downstream 
mechanisms for recognizing modulators are still unclear. Furthermore, histone 
methylations can be analyzed on a genomic scale by chromatin 
immunoprecipitation (ChIP) combined with DNA microarrays (ChIP-ChIP), ChIP 
combined with serial analysis of gene expression (ChIP-SAGE), or ChIP 
combined with high-throughput sequencing (ChIP-Seq) (Schones and Zhao, 
2008). 
The roles of histone lysine methylation have recently started to be 
investigated in neurons. For example, histone demethylases may be involved in 
neuronal differentiation (Jepsen et al., 2007), survival and dendritic development 
(Iwase et al., 2007). Enhanced levels of H3K4me3 and recruitment of a histone 
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methyltransferase, MLL1, accompany inhibitor of BRAF35 (iBRAF)-induced 
neuronal differentiation (Wynder et al., 2005) and decreased levels of H3K27me3 
at Dlx5 promoter are associated with neuronal differentiation (Jepsen et al., 2007). 
Hyper-trimethylation of H3K9 is correlated with striatal neuron atrophy in CREB 
binding protein (CBP) (+/-) mice (Lee et al., 2008). In addition, histone methylation 
is also linked to neuron-specific imprinting for lgf2r, and Grb10 (Vu et al., 2004; 
Yamasaki et al., 2005; Yamasaki-Ishizaki et al., 2007). Moreover, levels of 
H3K4me2 and H3K4me3 at the promoters of glutamate receptor genes are 
correlated with corresponding mRNA levels in the human cerebellar cortex 
(Stadler et al., 2005).  
Dysfunction of histone lysine methylation has also been implicated in 
psychiatric and neurological disorders. Regarding psychiatric diseases, X-linked 
mental retardation has been associated with histone demethylases such as 
SMCX and PHF8 (Iwase et al., 2007; Shi and Whetstine, 2007; Tahiliani et al., 
2007). Interestingly, SMCX is also linked to autism spectrum disorder (Adegbola 
et al., 2008). Remarkably, in schizophrenic PFC, down-regulated metabolic gene 
expression was linked to high levels of methylation at H3R17 (Akbarian et al., 
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2005). Moreover, in a mouse model of depression, chronic defeat-stressed mice, 
the gene for brain-derived neurotrophic factor (Bdnf) was regulated by increased 
dimethylation of histone H3 lysine 27 (H3K27me2) (Tsankova et al., 2006). 
 As to neurological diseases, the brains of humans and transgenic mice with 
Huntington’s disease (HD) showed increased levels of trimethylated H3K9 
(H3K9me3) and increased expression of SETDB1, a histone methyltransferase 
for H3K9 (Ryu et al., 2006). Interestingly, traumatically injured brains of immature 
rats showed decreased histone H3 methylation in the hippocampal CA3 region 
(Gao et al., 2006). Remarkably, brains from humans and transgenic mice with 
Friedreich ataxia (FRDA) were found to have increased di- and tri-methylation of 
H3K9 at the FXN/Fxn gene (Al-Mahdawi et al., 2008). Moreover, an aggressive 
brain tumor, glioblastoma multiforme, has been associated with decreased levels 
of JHDM1B, a histone demethylase for H3K4me3 at rRNA. This evidence 
implicated the potential association of H3K4me3 mark with brain diseases 
(Frescas et al., 2007).   
 DNA methylation. Mammalian DNA is methylated at cytosines within CpG 
dinucleotides that occur as CpG islands, which are regions containing a high 
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frequency (at least 55%) of CpG dinucleotides within 500-bp DNA sequences 
(Takai and Jones, 2002). CpG islands are enriched in the promoter regions and 
coding exons of the human genome (Saxonov et al., 2006), although CpG islands 
in promoter regions are more resistant to methylation than those in coding exons. 
Hypermethylation in promoters is associated with gene silencing, which is initiated 
by promoter-associated methyl-CpG-binding proteins (MBDs), which recruit 
transcriptional repressors such as histone deacetylases to silence gene 
transcription. An example of this function is provided by the X-linked 
methyl-CpG-binding-protein-2 (MECP2), which is mutated in 76% of patients with 
classic Rett syndrome (Van den Veyver and Zoghbi, 2000).  Hypermethylation at 
the promoters of tumor suppressor genes is also well known to be linked to 
cancer (Esteller, 2007). Furthermore, methylation in coding regions has been 
proposed to prevent internal initiation of transcription by recruiting histone 
deacetylases (Weber and Schubeler, 2007). DNA methylation doesn’t occur in all 
eukaryotes. No DNA methylation has been found in yeasts (Saccharomyces 
cerevisiae) or worms (Caenorhabditis elegans). Low levels of DNA methylation 
have been observed in insects (Drosophila melanogaster) and substantial levels 
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of methylation have been detected in honey bees (Apis mellifera) (Weber and 
Schubeler, 2007). 
 DNA methylation is catalyzed by 4 DNA methyltransferases (DNMTs): 
DNMT1, DNMT2, DNMT3a and DNMT3b (Hermann et al., 2004). DNMT1 is 
responsible for maintaining DNA methylation, whereas DNMT3a and 3b are 
responsible for de novo DNA methylation. Surprisingly, DNMT2 does not 
methylate DNA but does methylate cytosine 38 in the anticodon loop of tRNA (Asp) 
(Goll et al., 2006). DNMT1, 3a, and 3b are crucial for development because 
knockout for any of these DNMTs is lethal for mice (Okano et al., 1999; Chen et al., 
2007). In contrast, DNMT2-knockout mice are viable and fertile (Hermann et al., 
2003). Genome-wide mapping of DNA methylation first requires detecting DNA 
methylation by one of three methods (Zilberman and Henikoff, 2007) (1) bisulfite 
conversion, (2) methylation sensitive restriction enzymes or (3) affinity purification 
of methylated DNA (methyl-binding proteins or anti-methylcytosine antibody) to 
separate methylated from un-methylated DNA. Once detected, methylated DNA 
can be analyzed by high-throughput sequencing or DNA microarray (Zilberman 
and Henikoff, 2007). Interestingly, DNA methylation has been implicated in the 
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etiology of schizophrenia and bipolar disorder (Veldic et al., 2004; Costa et al., 
2007; Mill et al., 2008). 
 
Goals and rationales 
The molecular mechanisms underlying decreased GAD1 mRNA in 
schizophrenic PFC are still unclear. Moreover, schizophrenia is a 
neurodevelopmental disorder whose etiology has been implicated in interacting 
with environmental factors (Thapar et al., 2007). Therefore, my thesis work 
focused on determining which epigenetic determinants could play a role in the 
deficit of GAD1 mRNA in the PFC of schizophrenic brains. Understanding the 
roles of epigenetic factors in the pathogenesis of schizophrenia will advance 
knowledge about the development and treatment of schizophrenia. 
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CHAPTER II: CHROMATIN IMMUNOPRECIPITATION IN POSTMORTEM 
BRAIN 
The work presented in this chapter is reproduced from a study by Huang et al., 
published in J Neurosci Methods (Huang et al., 2006). 
This work was conducted under the direction of Dr. Schahram Akbarian, and 
it is with gratitude to him and the other authors that I reproduce these data for the 
purposes of this dissertation. My contributions to this work consisted of 
conducting all native chromatin immuoprecipitation, crosslinked chromatin 
immunoprecipitation, RT-PCR running, human and mouse primer design and 
tests, mouse brain preparation and data analysis. Anouch Matevossian 
contributed by assisting in the mouse primer tests and RT-PCR. Yan Jiang 
contributed by taking photos for Fig. 1-1. Dr. Akbarian contributed by making a 
cartoon for Fig. 1-2. The manuscript was primarily prepared by Dr. Akbarian while 
I contributed to the Materials and Methods, Figures and Legends, and provided 
feedback on other sections.  
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Abstract 
Histone modifications such as methylation could be involved in regulation of 
gene activity. However, modulation of gene status through histone methylation at 
different genomic loci is still unclear in human brains. Moreover, there has been 
no feasible method for chromatin immunoprecipitation applied to human 
postmortem brains so far. Two major concerns for this approach are autolysis time 
and tissue pH.  
We used micrococcal nuclease (MNase) – treated chromatin 
immunoprecipitation (NChIP) to profile histone methylation in human prefrontal 
cortex. NChIP was applied to mouse cerebral cortex in parallel with 
formaldehyde-crosslinking and sonication chromatin immunoprecipitation (XChIP). 
Interestingly, the integrity of mono-nucleosomes is still maintained 30 hrs after 
death. Furthermore, the differences of histone methylations at different genomic 
loci are detectable and stably preserved across a wide range of autolysis time and 
tissue pH. Surprisingly, MNase-treated chromatin was at least 10-fold more 
sensitive than crosslinked and sonicated chromatin in immunoprecipitation. 
Therefore, this approach is feasible for profiling of histone methylation in 
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postmortem brain. 
 
Introduction 
The dynamic change of chromatin structure is associated with regulation of 
gene activity. Moreover, methylation at N-terminal tails of histones reflects the 
chromatin structure. Interestingly, histone modifications could be involved in the 
etiology of complex diseases such as neuropsychiatric diseases (Tsankova et al., 
2007). However, little is known about epigenetic mechanisms of histone 
methylation in human brain. Furthermore, there is no feasible method available for 
chromatin immunoprecipitation in human postmortem brain. Recently, we showed  
“proof of principle” that methylation at histone lysine 4 is linked to developmental 
regulation and region-specific expression patterns of glutamate receptor genes in 
human cerebellum and prefrontal cortex (Stadler et al., 2005).  
The objectives of this study are to figure out (1) if the integrity of the 
mono-nucleosome, the basic unit of chromatin, in brain tissues is still maintained 
after a long period of time after death (2) whether the two major confounding 
factors, autolysis time and tissue pH, could degrade histone methylation at 
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different genomic loci and (3) if MNase-treated chromatin is more efficient in 
immunoprecipitation than crosslinked and sonicated chromatin in postmortem 
brain. Here, we showed that nucleosomal DNA is still attached to histone core 
after 30 hrs of autolysis time in postmortem brain. Histone methylations at 
different genomic loci are not affected by a wide range of autolysis time and tissue 
pH. Remarkably, the immunoprecipitation of chromatin is more efficient in the 
MNase-treated condition than in the crosslinked and sonicated condition. This 
method should be applied to study epigenetic mechanisms of gene regulation in 
normal and diseased human brains. 
 
Results 
Nucleosomal organization of genomic DNA is preserved in postmortem 
brain 
Nucleosome-bound genomic DNA is organized as an array of nucleosomes 
packaged into higher order structures for compartmentalization and compaction 
(Woodcock and Dimitrov, 2001). Previous studies on freshly prepared neurons 
had described a heterochromatic shell that separates the nucleolus from its 
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surroundings within the nucleus (Akhmanova et al., 2000). In tissue sections 
stained with the nucleophilic dye, DAPI, this shell and other condensed chromatin 
is visualized as intensely-labeled foci. Notably, neuronal nuclei in histological 
sections from postmortem cerebral cortex maintain DAPI-intense foci, including 
the shell that surrounds the nucleolus (Fig.1-1). Therefore, higher order chromatin 
structures appear to be preserved, at least partially, in postmortem brain. 
However, it is likely that autolysis after death leads to progressive disorganization 
of higher order chromatin and, ultimately, disintegration of nucleosomal arrays. 
Hypothetically, chromatin degradation in postmortem brain could be viewed as 
three progressive stages; in stage 1, higher order chromatin structures and 
nucleosomal arrays remain intact (Fig. 1-2A); in stage 2, there is chromatin 
fragmentation but nucleosomes are maintained and genomic DNA remains bound 
to core histones (Fig. 1-2B). In stage 3, DNA and core histones become detached 
and disintegrate (Fig. 1-2C). Importantly, the mapping of histone modification 
patterns at defined genomic sequences only requires that DNA:histone 
interactions, i.e. the nucleosomes as the fundamental unit of chromatin, are 
preserved in cadaver brain. To examine this, we treated homogenates from 
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cerebral cortex with micrococcal nuclease (MNase), a DNase that selectively 
spares DNA bound to the nucleosome core particle. After MNase treatment and 
gel electrophoresis, a robust, approximately 150-bp sized DNA fragment became 
visible both for human and mouse cerebral cortex subjected to autolysis for up to 
33 hours (Fig. 1-3A). As a control, genomic chromatin was stripped of protein 
prior to MNase treatment, and no DNA was detected (Fig. 1-3A). Furthermore, 
mouse cerebral cortex samples were immediately frozen after death and 
compared to autolytic samples from the same animal. There was no change in the 
intensity of the 150-bp fragment even after extended autolysis up to 33 hours (Fig. 
1-3B). We conclude that the bulk of nucleosome-bound genomic DNA remains 
attached to the core histones at least for 30 hours after death.  
 
Chromatin immunoprecipitation in human postmortem brain tissue reveals 
robust differences in histone methylation levels at various genomic loci  
Recently, we reported that, in the human brain, glutamate receptor gene 
promoters show differences in levels of histone methylation (Stadler et al., 2005). 
To confirm that histone methylation is detectable at regulatory sequences of 
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genes other than thoese encoding glutamate receptors, we quantified 
5’-regulatory sequences from four unrelated, single-copy genes (Table 1-2) by 
real-time PCR (Fig. 1-4A, B). Human samples were prepared by MN-digestion, 
followed by immunoprecipitation with anti-trimethyl-histone H3-lysine 4 
(anti-H3K4me3) and anti-trimethyl-histone-H3-lysine 27 (anti-H3K27me3) 
antibody. The H3K4me3 modification defines open chromatin at sites of actual or 
potential transcription, while the H3K27me3 modification defines silenced or 
condensed chromatin (Peterson and Laniel, 2004). We observed that the open 
chromatin-associated modification, H3K4me3, was comparatively high at the 
promoter of a housekeeping gene, 2-microglobulin (B2M), that shows stable 
expression in human postmortem brain (Mimmack et al., 2004) (Fig. 1-4C). In 
contrast, levels of the closed chromatin-associated modification, H3K27me3, 
were highest at the proximal promoter of GAD1, which encodes the 67kDa form of 
glutamic acid decarboxylase, which is expressed in GABAergic neurons that 
comprise 20% of cortical neurons (Hendry et al., 1987) (Fig. 1-4D). Furthermore, 
we found that the locus control region of the -globin locus, located 60kb 
upstream of the -globin gene (HBB), shows the lowest levels of histone 
30 
 
methylation (Fig. 1-4C, D). This observation is in good agreement with a recent 
study on various mouse and human cell lines showing lower levels of histone 
methylation at genomic sites further removed from proximal promoter sequences 
(Bernstein et al., 2005). We conclude that histone methylation levels in human 
postmortem brain show robust differences across various genomic sites, similar 
to recent observations made in freshly prepared extracts from dividing cells 
(Bernstein et al., 2005). 
 
Histone methylation levels in human cerebral cortex are maintained across 
wide ranges of autolysis time and tissue pH 
We wanted to find out if autolysis time and tissue pH, two commonly used 
indicators for the overall preservation of postmortem samples (Barton et al., 1993; 
Siew et al., 2004), affect results from chromatin immunoprecipitation assays. The 
differences in levels of methylated H3 (H3K4me3 and H3K27me3) between the 
various genomic loci were consistently observed in samples of a wide range of 
postmortem intervals (approximately 5-30 hours) and tissue pH (6.0 – 6.8) (Fig. 
1-5A-D). For each gene promoter (GAD1 and GRIN2B), the association between 
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postmortem intervals or tissue pH with histone methylation levels were very weak, 
with Pearson’s coefficient of determination (R2) ranging from 0.18 – 0.006, while 
the -globin locus (HBB) showed a moderate association with tissue pH (R2 = 
0.43) but not with postmortem interval (R2 = 0.016). Together, these findings 
suggest that postmortem factors such as tissue pH and autolysis time are not 
major confounds for chromatin immunoprecipitation assays with anti-histone 
antibodies. 
 
Comparing two alternative chromatin preparation techniques – enzymatic 
digestion versus crosslinking and sonication 
Chromatin fragmentation is necessary in order to immunoprecipitate 
molecular markers at sites of individual genes or specific genomic loci. We 
wanted to compare two alternative chromatin fragmentation methods, MNase 
digestion and formaldehyde-crosslinking followed by sonication (XSon) (O'Neill 
and Turner, 2003; Das et al., 2004). Cortical gray matter from adult mice was 
frozen immediately after death or subjected to autolysis for a period of 20 hours, 
and then prepared either by MNase or XSon for subsequent immunoprecipitation 
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with the anti-H3K4me3 antibody. The immunoprecipitation efficiencies, expressed 
as ChIP-to-input ratios, were for four out of four genes tested at least one order of 
magnitude higher in MNase-treated chromatin extracts, in comparison to XSon 
(Fig. 1-6). This finding was observed both in freshly frozen (Fig. 1-6A) and 
autolytic (Fig. 1-6B) tissue, suggesting that MNase digestion is the superior 
technique for the purposes of immunoprecipitation with anti-histone antibodies. 
Notably, for each of the 4 genes, ChIP-to-input ratios of MNase-treated chromatin 
extracts were very similar between freshly frozen and autolytic samples (Fig. 
1-6A, B). This result, obtained in mice, is in good agreement with our observation 
that in human brain, gene-specific histone methylation differences are not 
confounded by postmortem interval (Fig. 1-5B, D). 
 
Discussion 
The methodological study reported here demonstrates three key findings: (1) 
the structure of nucleosomes is still maintained in postmortem brain for at least 30 
hrs after death, (2) differences in levels of histone methylation at different genomic 
loci are detectable in postmortem brain and are preserved within a wide range of 
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autolysis time and tissue pH and (3) chromatin digested with MNase is more 
effective for subsequent immunoprecipitation as compared to the conventional 
method of formaldehyde-crosslinking followed by sonication. 
We observed that nucleosomal DNA is still attached to histones at least 30 hr 
after death in human and mouse postmortem brain. The autolysis time of most 
postmortem brains from human brain banks is within 30 hrs. Therefore, it is 
feasible to study histone modifications at different genomic loci from the available 
human postmortem brains. Another striking finding in this study is that histone 
lysine methylation at different genomic loci are maintained in postmortem brain 
even within a wide range of autolysis time and tissue pH. It has been shown that 
the turnover rate of histone methylation is similar to that of histone itself in 
mammalian cells (Borun et al., 1972; Byvoet et al., 1972; Thomas et al., 1972). 
Therefore, histone methylation will be an ideal histone mark in postmortem 
studies. Furthermore, histone modifications include not only methylation but also 
acetylation, phosphorylation, ubiquitination and sumoylation. It would be 
interesting to study the stability of those non-methylation modifications in 
postmortem brain.  
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Based on our results, we find that MNase-treated chromatin is much better 
for subsequent immunoprecipitation with anti-histone antibodies in comparison 
with crosslinked and sonicated chromatin. One study has shown that NChIP has 
higher signal-to-noise ratio in comparison to XChIP (O'Neill and Turner, 2003). 
Another advantage of NChIP is that most anti-histone antibodies are raised 
against native and unfixed antigens. MNase doesn’t destroy the native form of 
chromatin. Moreover, the amount of tissues we used in NChIP or XChIP is around 
50 mg of cortical gray matter. We didn’t enrich nuclei from tissue because nuclear 
membranes could be fragmented in frozen and autolytic conditions. It could be 
possible that purified nuclei or larger amounts of materials will increase the 
efficiency of XChIP. However, human postmortem brains are generally preserved 
in frozen condition from human brain banks and limited amounts of postmortem 
brains are available for researchers. Therefore, the NChIP procedure described 
here is superior to XChIP in postmortem brain. Another reason why NChIP is 
more suitable for postmortem tissue is that NChIP reduces artificial crosslinking 
with unrelated chromatin fragments. On the other hand, it could cause false 
association in ChIP assays. For instance, the three-dimensional structure of 
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chromatin such as the juxtaposition and clustering of nucleosomes from different 
chromosomal regions (Dekker, 2003) could become disorganized after death. 
As to the limitations of NChIP, it is more difficult to study protein of interest 
other than histones. The reason is that the basic requirement of NChIP is the 
stable interaction between the protein-of-interest and the genomic DNA in its 
native condition. Therefore, core histones are best choices for NChIP because of 
their strong interaction with nucleosomal DNA. Another concern for NChIP is that 
nucleosome spacing at defined genomic locus could differ in different samples. 
Moreover, the length of genomic DNA used in NChIP is around 146 bp in 
comparison with 500 to 1000 bp in XChIP. Fortunately, the patterns of histone 
methylation at orthologous loci are highly conserved between human and mouse 
even though many methylated sites don’t show sequence conservation (Bernstein 
et al., 2005). Therefore, changes in nucleosome spacing are unlikely to become a 
major confounding factor for NChIP. Furthermore, this potential confounding 
factor could be easily addressed by performing parallel immunoprecipitation 
experiments with two or more site- and residue-specific anti-histone antibodies. 
It is important to note that until now, analysis of mRNA levels was the only 
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method available to measure gene expression activity in postmortem human and 
primate brain (Hasenkamp and Hemby, 2002; Pongrac et al., 2002). We predict that 
chromatin-based approaches, including histone methylation mapping, will become 
a valuable complement to mRNA profiling and could provide mechanistic insight 
into transcriptional regulation of specific genes in healthy and diseased human 
brain. 
 
Materials and Methods 
Brain samples 
Tissue samples were dissected from Brodmann area 10 of postmortem 
prefrontal cortex of 16 normal adult subjects (Table 1-1), that were part of a brain 
collection at the University of California as previously described (Akbarian et al., 
2005). From each of the frozen samples, 75-100 mg of cortical gray matter was 
trimmed off and collected into microfuge tubes on dry ice, then stored at –80oC 
until further processed. Brains of adult, 8-16 week old, mice with mixed genetic 
background were removed from the skull, and the cerebral cortex of the left 
hemisphere frozen immediately on dry ice while the cerebral cortex of the right 
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hemisphere was kept untreated at room temperature for up to 33 hours before 
freezing. For all subsequent steps, the right and left cerebral cortex were 
processed in parallel. All procedures were approved by the Institutional Review 
Board and Animal Care and Use Committee of the University of Massachusetts 
Medical School.  
 
Micrococcal nuclease digestion 
The first step of the protocol is the enzyme-based digestion of chromatin 
fibers into mononucleosomes, using micrococcal nuclease as a DNAse that 
selectively spares nucleosome-bound genomic DNA. Each sample, 75mg (human) 
or 50 mg (mouse) of cerebral cortex, was homogenized in 375 (human) or 250 
(mouse) l ice-cold douncing buffer (DB) 10mM Tris.Cl [pH 7.5)]/4mM 
MgCl2/1mMCaCl2, and then incubated with 5 U/ml of micrococcal nuclease 
(MNase) (Sigma-Aldrich, St. Louis, MO, USA) for 7 min at 37oC. The DNase 
activity was stopped by adding EDTA to 10mM, and then a 10-fold volume excess 
of hypotonic lysis buffer (0.2mM EDTA [pH 8.0] /0.1mM benzamidine /0.1mM 
phenylmethylsulfonyl fluoride (PMSF)/1.5mM 1,4-dithio-DL-threitol (DTT) was 
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added and samples were incubated on ice for 60 min, with a brief vortexing at 10 
min intervals. The purpose of the hypotonic lysis buffer step is to extract the intact 
nucleosomes from cellular and nuclear debris of the postmortem tissue. Debris is 
then removed by centrifugation at 3000g. For each sample, 500 l were used for 
input control and gel electrophoresis and the remaining nucleosome-laden 
supernatant was divided into 1.6-ml aliquots for immunoprecipitations.  
 
Cross-linking and sonication 
Additional samples from mouse cerebral cortex (50 mg) were crosslinked at 
room temperature for 10 min in 1% formaldehyde / phosphate buffered saline 
(PBS). Crosslinking was stopped by adding glycine to a final concentration of 
0.125M. Samples were incubated at room temperature for 5 min, dounced and 
then pelleted by centrifugation, washed in PBS two times and then redisolved in 1 
ml of 100 mM Tris/ 100 mM NaCl/30 mM MgCl2 / 0.1% NP-40/ 0.1 mM PMSF, 
then dounced again, pelleted and dissolved in 300 l lysis buffer containing 1% 
SDS/ 10 mM EDTA / 50 mM Tris.Cl [pH 8.0]) / 0.1 mM PMSF. Samples were then 
sonicated, by applying ten 30 sec pulses at power level 6 (Branson, Danbury CT), 
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then centrifuged at maximum speed. The supernatant was diluted with 3x vol FSB 
buffer (5 mM EDTA/ 20 mM Tris.Cl [pH 7.5] / 50 mM NaCl) and divided into 
aliquots to serve as input and to be used for immunoprecipitation.  
 
Chromatin immunoprecipitation 
To each 1.6-ml aliquot of supernatant, 160 l of 10 x incubation buffer (IB, 50 
mM EDTA, 200 mM Tris.Cl, 500 mM NaCl, [pH 7.5], were added, together with 3.5 
l  of one of two site-specific antihistone antibodies: (i) anti-trimethyl-H3-lysine 4 
(H3K4me3) or (ii) anti-trimethyl-H3-lysine 27 (H3K4me27). Both antibodies were 
polyclonal (rabbit) and purchased from Upstate Biotechnology, Lake Placid, NY, 
USA. The specificity of these antibodies in chromatin immunoprecipitation assays 
has been established (Stadler et al., 2005); H3K4me3 is a marker for open 
chromatin and active transcription, while H3K4me27 primarily defines inactive and 
silenced loci within euchromatic regions. Samples were incubated overnight at 
4oC on a rotating wheel and then 90 l of protein G agarose slurry (Upstate) was 
added to each sample. The agarose has been pre-incubated twice in 1.6 ml of 1 x 
buffer IB and once in 1x buffer IB / 100 g/ml sonicated salmon sperm DNA. After 
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addition of protein G agarose, samples were incubated for 60 min at 4oC, then 
pelleted by gentle centrifugation at 100g for 30 sec, the supernatant removed and 
the agarose together with the captured immune complexes resuspended in 1 ml 
low-salt immune complex wash buffer [2mM EDTA/20mM Tris.Cl [pH 8.0]/500 mM 
NaCl/0.1% sodium dodecyl sulfate (SDS)/1% Triton X-100], after 3 min on a 
rotator, pelleted again and resuspended in high-salt immune complex wash buffer, 
[2mM EDTA/20mM Tris.Cl [pH 8.0]/500 mM NaCl/1%sodium dodecyl sulfate 
(SDS)/1% Triton X-100], then pelleted and resuspended in LiCl immune complex 
wash buffer (250 mM LiCl/1mM EDTA/10mM Tris.Cl [pH 8.0]/ 1% IGEPAL-CA360/ 
1% deoxycholic acid), after 3 min then washed twice in 1mL 1x TE (10 mM Tris.Cl 
[pH 8.0]/ 1mM EDTA). Captured immune complexes were eluted twice in 2x 250 
l elution buffer EB, freshly prepared on the day of the experiment [100mM 
NaCO3/1% SDS]. After elution and repeated centrifugation at 200g (to remove the 
agarose), EDTA to 10mM and 40 mM Tris.Cl [pH 6.5] were added to the 
supernatant and samples were digested with 50 g/ml proteinase K for at least 
2.5 hrs at 50oC, then purified by phenol-chloroform extraction, 
ethanol-precipitated with glycogen as carrier and dissolved in 50 l of sterile 4mM 
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Tris.Cl [pH 8.0]. Samples that had been crosslinked with formaldehyde were first 
incubated for 4 hours at 67oC to reverse crosslinks, then digested for 60 min with 
proteinase K prior to DNA extraction and purification.  
 
Quantification of immunoprecipitated DNA and selection of custom-made 
primers 
A DNA Engine Opticon 2 Light Cycler (MJ Research, Waltham, MA) was used 
for quantitative, real-time PCR with the DNA intercalating dye SYBR Green 
(Molecular Probes, Eugene, OR, USA), together with custom-made primers and a 
general PCR protocol, as described (Stadler et al., 2005). Primers were 
positioned within the first 1000 bp surrounding the transcription start sites of (a) 
GAD1, which encodes the 67kDa isoform of glutamic acid decarboxylase, (b) 
GRIN2B, the gene for the N-methyl-D-asparate (NMDA) receptor subunit NR2B, 
(c) the housekeeping gene B2M , 2-microglobulin, and (d) a regulatory element 
of the -globin locus (Table 1-2). Selected primer pairs had to fulfill 4 criteria; (i) 
product size within the range of 80-130 bp, in order to amplify from the 147 bp 
fragments of nucleosomal DNA, (ii) product specificity, as determined by 
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sequencing and single peak on SYBR Green-based melting curve; (iii) cycle 
thresholds consistently within the linear range of the amplification curve; (iv) an 
amplification efficiency within  25% of the theoretical maximum max = 1/ln2 = 
1.443.  Each PCR product from the chromatin immunoprecipitates (ChIPs) was 
normalized to sample input, using the equation V = (1+E) ct(Input-ChIP) , with E =max 
/ primer pair and the exponent defined as the differences in cycle threshold between 
ChIP and input.   
 
Immunohistochemistry 
Fresh frozen tissue blocks (frontal lobe) were thawed at room temperature 
and then immersion-fixed in 4% phosphate-buffered paraformaldehyde for 20 
hours, cryoprotected in 30% phosphate-buffered sucrose, frozen and cut in 
parallel series of 10-m thick sections that were collected in ice-cold PBS for 
free-floating immunohistochemistry. Sections were washed, incubated overnight 
at 40C in 0.3% Triton X-100/0.1M sodium phosphate [pH 7.4]/1:500 final dilution of 
anti-histone antibody (anti-H3K4me2 or anti-H3K4me3, rabbit polyclonal, Upstate) 
/ 1:500 final dilution of the SMI-32 antibody that binds to non-phosphorylated 
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neurofilament (mouse monoclonal, Sternberger Monoclonals/Covance, Berkeley, 
CA), washed, incubated for 60 min with FITC- and Texas-Red conjugated 
secondary antibodies (VectorLabs) in 1:200 final dilution, washed, slide-mounted, 
briefly air dried, counterstained with 4,6,-diamidino-2-phenylindole 
dihydrochloride (DAPI) and then coverslipped with Vectashield (VectorLabs). 
Sections were examined with a Zeiss Axiovert 200M microscope using a 63x, 1.4 
N.A. oil-immersion objective, a Retiga-1300R cooled CCD camera (Qimaging) 
using Slidebook 4.0 software (Intelligent Imaging Innovations). 
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Figure 1-1. Architecture of postmortem brain nuclei. (A,B) Digitized images of 
a neuronal nucleus from human cerebral cortex (87 year old individual, 8.5 hrs 
autolysis time); (A) Labeling with nucleophilic dye, DAPI, reveals numerous 
heterochromatic foci, including a shell (arrows) surrounding the nucleolus 
(asterisk); (B) Immunohistochemical labeling with anti-methyl-histone H3-lysine4 
antibody (FITC, green channel) and anti-neurofilament H (SMI-32) antibody 
(Texas Red). Note that histone immunoreactivity is confined to the nucleus and 
spares the nucleolus. Arrowhead in (A,B) marks non-neuronal nucleus. Images 
taken at 63x10 magnification.   
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Figure 1-2. Hypothetical scheme for progressive loss of chromatin 
organization during tissue autolysis. (A) shows freshly preserved nucleus, 
compartmentalized into loose, (“eu”-) and condensed (“hetero”-) chromatic 
regions, “Stage 1”; (B) nucleus from decomposing tissue, with the DNA still 
attached to core histones while higher order chromatin structures degenerate, 
“Stage 2”; (C) nucleus after advanced autolysis, with DNA now detached from 
histones and nucleosomes disintegrated, “Stage 3”. 
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Figure 1-3. Nucleosomal DNA is maintained in postmortem brain. (A) Images 
from ethidium bromide-stained 3% agarose gels showing prominent, 
approximately 150-bp DNA fragment in homogenates from cerebral cortex treated 
with micrococcal nuclease (MNase) and RNAse A. Left lane on each gel shows 
DNA ladder, arrowhead mark 500, 200 and 100 bp (top to bottom). H = human, 
M1, M2, M3 = mouse no.1-3, PMI = postmortem interval (hours). Notice 
prominent 150 bp band in human sample (11% of 80mg tissue) after 30 hours of 
tissue autolysis, but no detectable sample in negative control (n), defined as a 
sample that was stripped of protein by chloroform/phenol extraction prior to 
MNase digestion. Notice also prominent 150 bp band in both freshly preserved 
(PMI = 0 hrs) and autolytic (PMI = 5 (M2) and 33 (M3)) mouse cerebral cortex 
(each lane represents 17% of a 50 mg tissue sample). The weakly labeled higher 
MW DNA fragments are likely to represent polynucleosomes. (B) Graph 
comparing quantitative amount of 150 bp DNA after MNase treatment in autolytic 
cortex (x-axis, postmortem interval in hours), relative to samples from the same 
animals that were immediately frozen after death (y-axis, optical density autolytic / 
fresh frozen cortex). N=2 animals/time point.  
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Figure 1-4. Histone methylation levels at defined genomic sequences in 
human brain tissue. (A,B) Graphs illustrate quantitative PCR for B2M promoter 
sequences. (A) SYBR-green based melting curve from immunoprecipitates with 
anti-H3K4me3 and anti-H3K27me3 antibodies, showing single peak for specific 
product, (B) Amplification curves of inputs (red circle), immunoprecipitates (blue 
circle) and negative controls (green circle), dotted line indicating cycle threshold. 
(C,D) summarized ChIP-to-input ratios (y-axis) for 3 different genomic loci (HBB, 
GAD1, GRIN2B) (x-axis) after immunoprecipitation with anti-H3K4me3 (C) or 
anti-H3K27me3 antibody (D). Data are normalized to housekeeping gene, B2M. 
N= 10 samples/gene, data shown as mean  S.E.M.  
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
Figure 1-5. Autolysis time and tissue pH are not major confounds for 
chromatin immunoprecipitates from human postmortem brain. Graphs 
showing levels of H3K4me3 (A,B) and H3K27me3 (C,D) at GAD1, GRIN2B and 
HBB genes, normalized to B2M,  in relation to sample pH (A,C) or postmortem 
interval (B,D). Notice that differences in histone methylation levels between the 3 
genes are similar across the 16 samples despite variable autolysis time and 
tissue pH. (Linear regression model, R2 = 0.334 ~ 0.001) 
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Figure 1-6. Chromatin fragmentation by MNase treatment results in higher 
immunoprecipitation efficiencies. (A, B) Bar graphs show immunoprecipitation 
efficiencies, expressed as ChIP-to-input ratios (y-axis, log scale) of chromatin 
extracts prepared by MNase treatment (black bars) or crosslinking and sonication 
(XSon) (white bars); Samples are from mouse cerebral cortex, (A) immediately 
frozen after death, (B) collected after 20 hours of autolysis at room temperature. 
Data shown as mean  S.E.M. (N= 5 animals/group). Notice consistently higher 
ChIP-to-input ratios in MNase-treated samples, in comparison to XSon. Notice 
further that ChIP-to-input ratios are similar between MNase-treated samples from 
freshly preserved or autolytic cortex. * = P < 0.01 (Two sample t test) 
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Table 1-1: Postmortem brain collection 
N Age PMI Brain pH Gender 
  Mean ± SEM, y Mean ± SEM, hrs Mean ± SEM F/M, No. 
16 56.2 ± 5.5 13.7 ± 1.7 6.36 ± 0.06 7/9 
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Table 1-2: PCR primers for chromatin immunoprecipitation assays 
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CHAPTER III: PREFRONTAL DSYFUNCTION IN SCHIZOPHRENIA INVOLVES 
MIXED-LINEAGE LEUKEMIA 1-REGULATED HISTONE METHYLATION AT 
GABAERGIC GENE PROMOTERS 
This work presented here in this chapter is reproduced from a study by 
Huang et al., published in J Neurosci (Huang et al., 2007). 
This work was conducted under the direction of Dr. Schahram Akbarian, and it is 
with gratitude to him and the other authors that I reproduce these data for the 
purposes of this dissertation. My contributions to this work consisted of drug 
injection, mouse brain preparations, rat cell culture, immunofluorescence staining, 
native chromatin immunoprecipitation, crosslinked and sonicated chromatin 
immunoprecipitation, mRNA extraction, RT-PCR running, human, mouse and rat 
primers design and tests, in situ hybridization and cell counting, custom oligo 
array design and screen, data analysis. Anouch Matevossian contributed by 
assisting in mouse and rat primer tests, RT-PCR, native chromatin 
immunoprecipitation and mRNA extraction. Catheryne Whittle contributed by 
assisting in establishing and maintaining rat differentiated neuron cultures. Yin 
Guo contributed by assisting in immunofluorescence and DAB staining for Fig. 
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2-4A and human postmortem brain preparation. Se Young Kim contributed by 
assisting with the western blot of Fig. 2-4E. Dr. Schumacher provided Mll1 mutant 
mice. Dr. Baker contributed by assisting with the statistical analysis. Dr. Claudia 
Schmauss provided drd2-/-drd3-/- mice. The manuscript was primarily prepared by 
Dr. Akbarian, while I contributed to the materials and methods, figures and 
legends, and provided feedback on other sections. 
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Abstract 
Alterations in GABAergic mRNA expression play a key role in prefrontal 
dysfunction in schizophrenia and other neurodevelopmental diseases. Here we 
show that histone H3-lysine 4 methylation, a chromatin mark associated with the 
transcriptional process, progressively increased at GAD1 and other GABAergic 
gene promoters (GAD2, NPY, SST) in human prefrontal cortex (PFC) from 
prenatal to peripubertal ages and throughout adulthood. Alterations in 
schizophrenia included decreased GAD1 expression and H3K4-trimethylation, 
predominantly in females and in conjunction with a risk haplotype at the 5’ end of 
GAD1. Heterozygosity for a truncated lacZ knock-in allele of mixed-lineage 
leukemia 1 (Mll1), a histone methyl-transferase expressed in GABAergic and 
other cortical neurons, resulted in decreased H3K4 methylation at GABAergic 
gene promoters. In contrast, Gad1 H3K4 (tri)methylation and Mll1 occupancy was 
increased in cerebral cortex of mice after treatment with the atypical antipsychotic, 
clozapine. These effects were not mimicked by haloperidol or genetic ablation of 
dopamine D2 and D3 receptors, suggesting that blockade of D2-like signaling is 
not sufficient for clozapine-induced histone methylation. Therefore, chromatin 
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remodeling mechanisms at GABAergic gene promoters, including MLL1-mediated 
histone methylation, operate throughout an extended period of normal human 
PFC development and play a role in the neurobiology of schizophrenia. 
 
Introduction 
Prolonged maturation of the prefrontal cortex (PFC), extending into or even 
beyond the second decade, plays a key role in normal human development and 
the neurobiology of major psychiatric disease, including schizophrenia 
(Weinberger, 1987). In the adolescent non-human primate PFC, dynamic changes 
in the levels of GABAergic marker proteins suggest a role for inhibitory circuitry 
(Lewis et al., 2004), but little is known about the underlying molecular mechanisms. 
Traditionally, expression studies on brain (including human) were confined to 
quantification of mRNA and protein, but this approach does not discriminate 
between various cellular mechanisms such as gene transcription as opposed to 
translational or other post-transcriptional regulatory pathways. There is evidence, 
however, that psychosis and other psychiatric diseases are accompanied by 
molecular alterations related to epigenetic control of gene expression 
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(Abdolmaleky et al., 2004; Petronis, 2004; Grayson et al., 2005; Tsankova et al., 
2007). Here, we show that maturation of human PFC and rodent cerebral cortex is 
accompanied by progressive increases in GABAergic mRNA levels, including 
GAD1 which encodes a key enzyme for GABA synthesis that is regulated by 
neuronal activity (Benson et al., 1994) and which is frequently affected in 
schizophrenia and related disease (Akbarian et al., 1995; Heckers et al., 2002; 
Veldic et al., 2005; Lewis and Gonzalez-Burgos, 2006). These developmentally 
regulated changes in mRNA levels were associated with dynamic chromatin 
remodeling at GAD1/Gad1 and other GABAergic gene loci, as reflected by 
increased methylation of histone H3-lysine 4. This included the trimethylated form, 
H3K4me3, a type of histone modification linked to transcriptional mechanisms and 
RNA polymerase II activity (Hampsey and Reinberg, 2003; Sims et al., 2003). We 
report that H3K4 methylation, including H3K4me3, was down-regulated at Gad1 
and other GABAergic genes in mice heterozygous for a targeted allele of Mll1 
(mixed leukemia-lineage 1), a histone methyltransferase that is expressed at 
robust levels in cortical interneurons. Interestingly, treatment with the atypical 
antipsychotic, clozapine, resulted in increased Mll1-occupancy and H3K4me3 
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levels at the Gad1/GAD1 promoter. Finally, we demonstrate that schizophrenia 
subjects having biallelic for GAD1 haplotypes previously associated with 
schizophrenia and mood and anxiety disorders (Addington et al., 2005; Lundorf et 
al., 2005; Hettema et al., 2006; Straub et al., 2007a) had a deficit in prefrontal 
GAD1 mRNA, in conjunction with a shift from open (H3K4me3) towards repressive 
(H3K27me3) chromatin-associated histone methylation. These novel findings 
present the first evidence that MLL1-mediated histone lysine methylation is an 
important regulator of GABAergic chromatin structures that are dynamically 
regulated throughout an extended period of human PFC development and 
involved in the pathophysiology of chronic psychotic illness, including 
schizophrenia.   
 
Results 
Dynamic changes in GAD1 expression during human PFC development   
To determine the regulation of GAD1 expression during maturation of human 
PFC, we monitored GAD1 transcript levels from the second trimester of pregnancy to 
old age, using qRT-PCR (GAD1 and 18S rRNA for normalization) in conjunction with 
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multiple primer pairs in 55 postmortem samples. There was a progressive increase in 
GAD1 mRNA levels throughout pre- and postnatal development and childhood until 
the peripubertal stage, which was followed by a plateau or mild decline during 
subsequent aging (Fig. 2-1A). Developmental changes for GAD2, a glutamic acid 
decarboxylase isoform encoded by a different gene, were similar to GAD1 but less 
pronounced. Levels were lowest in the prenatal specimens, peaked before puberty 
followed by intermediate levels in the adult (fetal (mean ± S.E.M.), 4.5 ± 0.9 vs. child 
(<12 years old) 11 ± 1.4, p = 0.003, ANOVA Tukey HSD; adult 7.0 ± 1.0) (data not 
shown). Gad25 and Gad44, two spliced forms of Gad1, express predominantly in a 
short period of time in mouse embryonic brains (Gad25: E10.5-E12.5; Gad44: 
E12.5-E15.5). Gad44, but not Gad25, has GABA synthesis activity (Chessler and 
Lernmark, 2000; Varju et al., 2002). Maturation of GABAergic neurons occurs 
postnatally instead of prenatally (Del Rio et al., 1992). Therefore, we didn’t address 
whether an imbalance of Gad25 and Gad44 expression could contribute to the 
etiology of schizophrenic.  
 
Progressive methylation of H3-lysine 4 at GABAergic gene promoters 
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during PFC development  
 To determine whether a transcriptional mechanism, including chromatin 
remodeling, contributes to the extended regulation of GAD1 mRNA expression, 
we measured histone lysine methylation levels at the GAD1 locus in PFC 
nucleosomal preparations, using NChIP (O'Neill and Turner, 2003; Huang et al., 
2006) in conjunction with modification-specific anti-histone antibodies, and rabbit 
serum as negative control (Fig. 2-1B-E). In adult PFC, open (H3K4) and 
repressive (H3K27) chromatin-associated methylation marks showed peak levels 
in nucleosomes positioned within the first 2kb upstream (H3K27) or downstream 
(H3K4) of the GAD1 transcription start site (TSS) (Fig. 2-1C). Very similar findings 
were obtained for Gad1 chromatin from mouse cerebral cortex (Fig. 2-2A). 
Therefore, regulation of histone methylation in human and rodent cerebral cortex 
bears similarities to various other tissues and cell lines for which clustering of 
histone methylation signals around TSS in chromosome-wide scans have been 
reported (Schneider et al., 2004; Bernstein et al., 2005). Next, we monitored 
levels of H3K4me3, and of H3-mono-methyl-lysine 4 (H3K4me1) – a related 
modification that partially overlaps with H3K4me3 in genome-wide screens 
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(Heintzman et al., 2007) – around the GAD1 TSS during the course of PFC 
development. Similar to the progressive up-regulation in GAD1 mRNA levels, 
H3K4me3 levels at the GAD1 promoter showed a several-fold increase from fetal 
to childhood and from childhood to postpubertal/adult stages (Kruskal-Wallis, p < 
0.001 & Dunn’s test, p < 0.01) (Fig. 2-1D). Similar changes were observed for the 
monomethylated form, H3K4me1 (Kruskal-Wallis, p < 0.01 & Dunns’ test, p < 0.05) 
(Fig. 2-1E). This developmentally regulated increase in H3K4 tri- and 
mono-methylation at the GAD1 locus is not explained by a generalized increase in 
histone methylation levels, because nucleosomes positioned at the locus control 
region of the erythropoetic -globin locus, and around a telomere-associated DNA 
repeat remained at very low levels throughout all stages of PFC development (Fig. 
2-1D). To examine if GABAergic genes other than GAD1 undergo chromatin 
remodeling during the course of PFC development, we measured H3K4 
methylation at the 65 kDa glutamate decarboxylase (GAD2), somatostatin (SST) 
and neuropeptide Y (NPY) gene loci. All GABAergic gene loci showed a 
developmental increase in methylated H3K4 (Fig.2-1D, E). For the tri-methylated 
form, H3K4me3, levels were again highest in the postpubertal/adult age group 
67 
 
(GAD2, SST, Dunn’s test, p <0.01) (Fig. 2-1D) while monomethylated H3K4 at 
these loci peaked during childhood (GAD2, SST, NPY, Dunn’s test, p <0.01) (Fig. 
2-1E). We conclude that developmentally regulated chromatin remodeling in 
human prefrontal cortex is not limited to GAD1 but affects additional GABAergic 
gene loci.  
 
Chromatin remodeling at GABAergic gene loci during neuronal 
differentiation 
Our studies on human postmortem PFC suggest that histone methylation at 
GABAergic gene promoters is dynamically regulated during an extended period of 
development. Next, we wanted to determine whether similar mechanisms operate 
in developing mouse cerebral cortex. Indeed, H3K4me3 levels at the proximal 
Gad1, Sst and Npy promoters, and the corresponding gene transcripts, were 
progressively up-regulated during development of mouse cerebral cortex (Fig. 
2-2B, D). Remarkably, these dynamic changes continued beyond postnatal day 
18 (P18), or 10 days after the density of cortical GABAergic neurons had reached 
adult levels (One way ANOVA with Tukey HSD, p < 0.05 – 0.001) (Fig. 2-2B, C).  
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These developmental changes in GABAergic mRNA expression and histone 
methylation shifts at the corresponding gene promoters were further tested in 
neural precursor cells cultured from E14.5 rat brain which differentiate into 
GABAergic and other neurons upon withdrawal of fibroblast growth factor 2 
(FGF2) from the medium (Fig. 2-3A, B) (Laeng et al., 2004). As expected, Gad1 
and Npy mRNA levels were up-regulated in cultures following FGF2 withdrawal, 
while changes in Sst transcript were not significant (Fig. 2-3C). Interestingly, these 
effects on Gad1 and Npy expression were further enhanced in cultures exposed 
to valproate (0.5 mM) or phenylbutyrate (0.5 mM), two short chain fatty acids 
acting as histone deacetylase inhibitors (HDACi) (Fig. 2-3C). We conclude that 
expression of a subset of GABAergic genes in neuronal culture is affected by 
exposure to chromatin modifying drugs. Furthermore, the up-regulation in 
Gad1/Npy transcripts in these differentiated cultures was associated with 
significant, 24-fold (Gad1) and 4-fold (Npy) increases in the open chromatin mark, 
H3K4me3, at the corresponding promoter (Fig. 2-3D). In contrast, 
differentiation-related histone methylation changes at the Sst gene locus were not 
significant (Fig. 2-3D). Finally, the repressive chromatin mark, H3K27me3, was 
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down-regulated at all 3 gene promoters (Gad1/Npy/Sst) upon differentiation 
although these decreases didn’t reach the level of siginificance (Fig. 2-3E). 
Further study for the crosstalk between histone acetylation and methylation is 
needed. 
 
The histone methyltransferase mixed-lineage leukemia 1 (Mll1) is expressed 
in cortical interneurons and regulates H3K4 methylation at GABAergic gene 
promoters  
To explore the molecular mechanisms that regulate histone methylation at the 
GAD1 locus, custom-made oligonucleotide arrays were used to profile the 
developmental expression pattern of approximately 30 histone 
methyltransferases and associated co-factors, including 4 transcripts encoding 
enzymes with H3K4 methyltransferase activity (MLL1, MLL2, SMYD3, SET7) and 
several co-factors specifically associated with methylation of           
H3-lysine 4 (Fig. 2-4Ba). Among the methyl-transferase encoding transcripts, only 
MLL1 (mixed lineage leukemia factor 1) was expressed at robust levels in both 
the adult human prefrontal cortex (Fig. 2-4Ba) and mouse cerebral cortex (Fig. 
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2-4Bb). Expression of Mll1-immunoreactivity was observed in numerous nuclei 
positioned across the full vertical thickness of the mouse cerebral cortex (Fig. 
2-4Aa). These included a significant portion of GABAergic interneurons as 
evidenced in sections double-labeled for Mll1 protein and Gad1 protein (Fig. 
2-4Ab) or Gad1 transcript (Fig. 2-4Ac).  
These high levels of Mll1 immunoreactivity in cortical interneurons suggest a 
role for that enzyme in the regulation of GABAergic chromatin. Indeed, there was 
robust Mll1 occupancy at the proximal Gad1 promoter in mouse P8 and P105 
cortical chromatin extracts prepared by formaldehyde crosslinking and sonication 
(Fig. 2-4C). It is thought that MLL1-mediated H3K4 trimethylation is under the 
control of the transcriptional process (Hampsey and Reinberg, 2003; Eissenberg 
and Shilatifard, 2006). In dividing cells, the genome-wide positioning of Mll1 
overlaps to 90% with RNA polymerase II occupied regions (Guenther et al., 2005). 
Notably, mice homo- or  heterozygous for a truncated Mll1 allele lacking the 
methyltransferase (SET) domain showed deficiencies in H3K4 tri- and 
di-methylation (H3K4me3 and H3K4me2) at selected Hox and other gene loci 
(Milne et al., 2005). Homozygosity for this Mll1 allele is lethal at E10.5 and mutant 
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embryos exhibit segmentation defects in cranial ganglia and branchial arches (Yu 
et al., 1995; Yu et al., 1998).  Interestingly, recent analysis of newborn brains and 
adult hippocampus from viable Mll1+/- mice identified increased Mll1 protein 
levels in conjunction with decreased Mll1 mRNA expression, suggesting a 
post-translational mechanism of Mll1 upregulation (Kim et al., 2007).  Therefore, 
we examined H3K4me3 and H3K4me2 at Gad1/Sst/Npy in cerebral cortex of 
adult Mll1+/- animals. In the mutants, H3K4me3 was decreased by 42-57% and 
H3K4me2 by 15-31%, in comparison to controls (Fig. 2-4D). These methylation 
changes at GABAergic promoters were, as a group, significant (Binomial Test 
[6/6], p = 0.03). Notably, decreased promoter histone methylation in Mll1+/- mice 
was not accompanied by consistent reductions in the corresponding gene 
transcripts (data not shown), consistent with the hypothesis that Mll1-mediated 
histone methylation operates downstream from the transcriptional process 
(Hampsey and Reinberg, 2003; Eissenberg and Shilatifard, 2006). Furthermore, 
bulk histone preparations revealed no statistically significant difference in 
H3K4me2 and H3K4me3 levels between wild-type and Mll1 heterozygous brain 
(Fig. 2-4E).  In the context of normal bulk histone methylation, decreased H3K4 
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methylation at Gad1/Sst/Npy suggests that Mll1 functions at a select number of 
target loci in adult brain. 
 
GAD1 SNPs are associated with chromatin alterations in prefrontal cortex of 
schizophrenia subjects  
We profiled GAD1 and GAD2 histone methylation patterns (H3K4me3 and 
H3K27me3) and mRNA levels in a postmortem collection of 36 schizophrenia 
subjects (12 females, 24 males), using a case/control design. There were no 
significant alterations in GAD2 mRNA and histone methylation levels 
(Supplemental Figure 2-1, panel A). In contrast, significant deficits were observed 
for GAD1 mRNA and H3K4me3 levels in female, but not male schizophrenia 
subjects (Fig. 2-5A). Notably, schizophrenia in females is associated with a later 
age-of-onset as compared to males (Lieberman et al., 2001). Therefore, the 
deficits in GAD1 mRNA and H3K4me3 in the schizophrenia cohort of the present 
study showed a highly robust, inverse correlation with age-of-onset (Fig. 2-5B). 
The molecular mechanisms mediating this gender- and age-of-onset related effect 
remain to be explored. Interestingly, prefrontal MLL1 expression was significantly 
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higher in females as compared to males; levels were similar in cases and controls 
(Supplemental Figure 2-1, panel B).  Furthermore, the steep and progressive 
increase in GAD1 H3K4me3, which was observed during pre-pubertal 
development (Fig. 2-1D), continued on a moderate level also throughout 
subsequent maturation and aging of normal prefrontal cortex (Fig. 2-5C). 
Therefore, histone methylation at the GAD1 locus – in addition to its regulation 
during early brain development – is also a molecular mechanism potentially 
operating throughout early and late stages of psychotic illness.  
Several GAD1 SNPs confer genetic risk for increased rate of frontal lobe gray 
matter loss, in conjunction with childhood-onset and other types of schizophrenia 
(Addington et al., 2005; Straub et al., 2007a), and bipolar illness (Lundorf et al., 
2005). Given the proximity of these SNPs to the transcription start site (TSS) of 
GAD1 (Fig. 2-5D), we hypothesized that changes in GAD1 chromatin structure 
could contribute to cortical pathology in genetically susceptible individuals. We 
genotyped GAD1 SNPs and found that allele frequencies were not significantly 
different between disease and control brains (data not shown). A subset of 3 
SNPs were selected for further analyses because >10% of cases were 
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homozygous for the rare allele, indicating sufficient statistical power. We then 
determined the frequencies of cases that, in comparison to the matched controls, 
showed decreased prefrontal GAD1 mRNA levels, in conjunction with a decrease 
in the open chromatin mark, H3K4me3 and elevated levels of the repressive mark, 
H3K27me3. Given these criteria, 35% of schizophrenia subjects (male and female, 
see legend of Fig. 2-5D) biallelic for the GAD1 SNPs previously identified as risk 
factors for schizophrenia (Addington et al., 2005; Straub et al., 2007a) or bipolar 
disorder (Lundorf et al., 2005) (genotype 1/1 in Fig. 2-5D) were affected. Strikingly, 
neither of the other two genotypes (genotypes 1/2 and 2/2, Fig. 2-5D) was 
detected in the patients meeting these criteria. These differences were significant 
(Fisher-Freeman-Halton, p< 0.05). For the matched controls, there were no 
significant differences in distribution of allelic loads (data not shown). We 
conclude that genetic polymorphisms around the proximal GAD1 promoter play 
an important role for chromatin alterations and transcriptional dysregulation in 
schizophrenia subjects.  
 
Mll1 occupancy and H3K4 trimethylation at the Gad1 promoter in cerebral 
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cortex is selectively increased after treatment with the atypical 
antipsychotic clozapine  
Previous studies reported increased Gad1 mRNA expression in rodent 
cerebral cortex after chronic antipsychotic drug treatment (Lipska et al., 2003; 
Zink et al., 2004; Chertkow et al., 2006). In order to test if chromatin remodeling is 
involved, Gad1 H3K4me3 levels were monitored after daily injections of clozapine 
(5mg/kg) for 21 days. Clozapine is an atypical antipsychotic drug with relative 
efficiency in treatment-resistant schizophrenia and for some of the cognitive 
deficits of that disorder (Meltzer, 2004). Indeed, after chronic clozapine treatment, 
Gad1-associated H3K4me3 was increased 3-fold in cerebral cortex, in 
comparison to vehicle-treated controls (One way ANOVA with Tukey HSD, p < 
0.05) (Fig. 2-6A). Because clozapine’s pharmacological profile extends beyond 
antagonism of dopamine D2-like receptors, we also monitored Gad1 H3K4me3 
after chronic treatment with the conventional antipsychotic and D2-like antagonist, 
haloperidol (0.5 mg/kg/day x 21 days). No significant changes were observed (Fig. 
2-6A). Furthermore, no changes in H3K4 methylation were observed in cortical 
Gad1 chromatin from compound mutant mice homozygous for null alleles of the 
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Drd2 and Drd3 dopamine receptor genes (Glickstein et al., 2002) (Fig. 2-6A). 
Therefore, blockade of D2-like receptors is not sufficient to explain the 
clozapine-induced increase in histone methylation at the Gad1 promoter.  
Notably, Mll1 mRNA expression in mouse cerebral cortex was increased after 
chronic clozapine treatment (Fig. 2-6B). In addition, Mll1-occupancy at the Gad1 
promoter showed a significant 2-fold increase after a single dose of 5mg/kg 
clozapine (Fig. 2-6B). This clozapine-regulated Mll1 occupancy at Gad1 
chromatin was evident both at 30 min (236% ± 72% relative to controls, N=12) 
and 120 min after the injection (291% ± 110% relative to controls, N=12). In 
contrast, Gad1/Mll1-occupancy 30 min after a lower dose of clozapine (1mg/kg) 
remained unchanged relative to controls (97% ± 16%, N=6).  Furthermore, the 
clozapine-mediated Mll1 recruitment at Gad1 chromatin was specific for that locus, 
because Mll1 occupancy at the Sst promoter was indistinguishable between 
drug-treated animals and controls (data not shown). We conclude that 
clozapine-induced histone methylation at the Gad1 locus involves two steps, 
which are increased Mll1 expression and recruitment to the GABAergic promoter.  
In order to investigate whether clozapine’s effects on Gad1 methylation, as 
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described above for mouse cerebral cortex, also apply to the human prefrontal 
cortex, we obtained postmortem specimens from another 9 schizophrenia 
subjects that were treated with clozapine prior to death. In comparison to 
schizophrenia subjects treated with typical antipsychotics but otherwise closely 
matched for age, gender, RNA quality and allelic load for GAD1 risk alleles 
(Supplemental Table 2-1), the clozapine-treated subjects showed on average a 
2-fold higher level of H3K4me3 at the GAD1 locus. This difference between the 
two groups was significant (Fig. 2-6C). In contrast, there were no consistent 
differences in H3K27me3 levels between the two treatment groups. Furthermore, 
the clozapine-treated subjects showed a modest, albeit non-significant increase in 
mRNA levels for GAD1 and MLL1 (Supplemental Figure 2-1, panel C, D). There is 
no change of Gad1 mRNA levels after either acute or chronic clozapine treatment 
(data not shown). Taken together, the animal studies and the human data support 
the notion that clozapine positively regulates MLL1-mediated histone methylation 
at the GAD1 locus. 
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Discussion 
We report that maturation of human and rodent cerebral cortex is reflected by 
a progressive increase in histone H3-lysine 4 methylation at GABAergic gene 
promoters. Regulation of chromatin structures at a subset of GABAergic gene loci, 
including GAD1/ Gad1, was dependent on normal gene dosage for Mll1, a histone 
methyl-transferase expressed in GABAergic interneurons. These chromatin 
remodeling mechanisms are likely to play an important role for 
schizophrenia-related pathophysiology, because Gad1/GAD1-associated H3K4 
methylation, and Mll1 occupancy, were upregulated after treatment with the 
atypical antipsychotic clozapine, a drug that improves working memory and other 
frontal lobe-associated cognitive functions (Meltzer, 2004). Notably, 
polymorphisms around the GAD1 promoter previously associated with 
schizophrenia and accelerated loss of frontal lobe gray matter (Addington et al., 
2005; Straub et al., 2007a) also correlate with, according to the present study, 
deficits in gene expression and histone methylation alterations in schizophrenia 
brain. Therefore, Mll1/MLL1-mediated histone lysine methylation at GABAergic 
gene loci emerges as a molecular link that interconnects three major factors in the 
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neurobiology of psychosis: developmental mechanisms, interneuron dysfunction 
and antipsychotic pharmacotherapy.  
 Importantly, the present study faces two limitations. First, it remains unclear 
why the observed deficits in GAD1 mRNA levels and H3K4 methylation occur 
predominantly in female subjects with schizophrenia (Fig. 2-4A). Notably, the 
genetic association of GAD1 haplotypes with schizophrenia is reportedly more 
robust in females than in males (Addington et al., 2005; Straub et al., 2007a). It 
remains possible that the gender-specific effects in these genetic studies and in 
the present postmortem study are, at least in part, due to higher levels of MLL1 
expression in PFC of females as compared to males (Supplemental Fig. 2-1, panel 
B).  Second, it remains unclear if and how the observed upregulation of H3K4 
methylation at the Gad1/GAD1 promoter of clozapine-treated mice (Fig. 2-5A) and 
human subjects (Fig. 2-5B) reflects functional changes in the cortical GABAergic 
system, given that the corresponding changes in steady state GAD1 mRNA levels 
were more subtle and without statistical significance (Supplemental Figure 2-1, 
panel D). Notably, evidence from animal models suggest that clozapine, in 
contrast to conventional antipsychotic drugs blocking D2-receptors, selectively 
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improves GABAergic circuitry functions in cerebral cortex (Pillai-Nair et al., 2005) 
possibly by enhancing inhibitory inputs onto pyramidal neurons through a 
network-based mechanism (Gao, 2007). In agreement with this hypothesis, 
clozapine-regulated methylation of GABAergic chromatin – as reported here for 
the animal and human brain – requires functional brain circuitry, because 
Gad1-H3K4 methylation remains unaffected in neuronal cultures treated with 
clozapine (Huang and Akbarian, 2007). Therefore, further studies will be 
necessary to explore the link between GABAergic chromatin remodeling and the 
electrophysiological changes (Gao, 2007) after clozapine treatment.  
Beyond its biochemical function as a histone methyltransferase with 
specificity for H3 lysine 4 (Milne et al., 2002), recent evidence points to a distinct 
developmental role of Mll1 in the central nervous system.  This was evident from 
segmentation defects in cranial ganglia in Mll1 -/- embryos (Yu et al., 1998), as 
well as abnormal synaptic plasticity in the hippocampus of Mll1+/- adult mice (Kim 
et al., 2007). In support of multiplicity of function, Mll1 undergoes highly regulated 
proteolytic cleavage (Yokoyama et al., 2002) and was recently detected in a 
complex with the Polycomb protein Eed and repressive chromatin remodeling in 
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the adult brain (Kim et al., 2007). This suggests that Mll1 regulates CNS circuitry 
through several mechanisms operating at different stages of development, as well 
as in adult brain. Furthermore, the dynamics and molecular machineries regulating 
histone methylation and de-methylation (Etchegaray et al., 2006; Tahiliani et al., 
2007) in CNS await further investigations.  
It will also be of interest to find out whether or not GAD1 H3K4 histone 
hypomethylation in schizophrenia, as reported here, is accompanied by epigenetic 
modifications of the genomic DNA, including methylation of CpG dinucleotides. 
However, according to a preliminary study on a small subset of CpG’s positioned 
in the 5’ portion of GAD1, DNA cytosine methylation frequencies at the GAD1 
promoter are very low in normal human PFC (<5%) and potentially even further 
decreased in repressive (H3K27me3) but not open (H3K4me3) chromatin of 
schizophrenic subjects (Huang and Akbarian, 2007). Therefore, comprehensive 
mapping of multiple histone modifications, and DNA CpG methylation tags, at 
GAD1 and other GABAergic gene loci will be necessary in order to better 
understand epigenetic regulation of GABAergic gene expression in healthy and 
diseased human PFC. 
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It is remarkable that, according to the present study, chromatin structures in 
prefrontal cortex are subjected to progressive changes from prenatal to 
peripubertal stages. In addition, this process continues at some gene loci, 
including GAD1, throughout adulthood into old age. This implies that chromatin 
remodeling and transcriptional mechanisms function as part of a molecular “clock” 
that regulates, over the course of many years, the protracted maturation, and 
perhaps also subsequent aging, of prefrontal GABAergic circuitry.  To gain 
further insight into this clock bears great promise for a better understanding of 
normal human development, including possible alterations in schizophrenia and 
related disease. 
 
Materials and methods 
Human subjects 
Human postmortem samples included in this study were obtained from the 
dorso-rostral pole of the frontal lobe, corresponding to Brodmann’s Area 10 of 
adult cortex. All procedures were approved by the Institutional Review Boards of 
the participating institutes. All brains were fresh-frozen and stored at -80oC. The 
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fetal, neonatal and child samples were obtained through the Brain and Tissue 
Banks for Development Disorders, University of Maryland (NICHD contract no. 
NO1-HD-8-3284). In addition, 50 subjects diagnosed with schizophrenia and 
matched controls were obtained from a brain bank located at the University of 
California at Davis (UCD) and a brain bank at Maryland Psychiatric Research 
Center, Baltimore, Maryland (Akbarian et al., 2005). Matching was done for 
gender and also for age and autolysis time (± 25%). All matching procedures were 
completed prior to any experiment, including genotyping and determination of 
RNA integrity numbers (RIN). When an RIN value of 4.0 was chosen as the cut-off 
for acceptable RNA quality (Lipska et al., 2006), 14/50 matched pairs were 
removed from this study. Demographics, medication status and postmortem 
confounds, including tissue pH and RIN for the remaining 36 matched pairs are 
provided in Supplemental Table 2-1. Because none of these 36 cases had 
received clozapine, an additional set of 9 cases (all treated with clozapine prior to 
death) was obtained from the Maryland Psychiatric Research Center and also the 
Bronx VA Medical Center, Mount Sinai School of Medicine. The serum levels of 
clozapine in the toxicology screens after death ranged from 0.7 – 5.6 mg/L. The 
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36 matched pairs of this study include 10 matched pairs (4 female, 6 male) from a 
previous study focused on GAD1 DNA cytosine methylation in PFC of 
schizophrenia subjects (Huang and Akbarian, 2007). 
 
Animal studies 
For antipsychotic drug studies, adult male C57BL/6J mice (JAX), 10-15 weeks of 
age, were treated acutely or for 21 days with once daily i.p. injections of saline or 
haloperidol (0.5 mg/kg) or clozapine (5 mg/kg) (Sigma), then sacrificed 0, 30 and 
120 min (acute) or 60 min (chronic) after the last treatment. Mutant mice included 
in this study (Mll1+/-, Drd2-/-Drd3-/-) were 10-15 weeks old and gender-matched 
to animals from an outbred colony (Mll1) (Kim et al., 2007) or inbred strain 
(Drd2-/-Drd3-/-, C57Bl6) (Glickstein et al., 2002). Cerebral cortex, without 
hippocampus, was isolated, for RNA extraction (left hemisphere) and chromatin 
immunoprecipitation (right hemisphere).  
 
Cell cultures 
Neural precursor cells were prepared from forebrain of E14.5 SASCO SD rat 
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embryos (Charles River). Live cells were plated out at 1.2-1.4x106 cells per 
100-mm poly-l-lysine coated dishes pre-coated with 15 g/ml poly-l-ornithine 
(Sigma) and 1g/ml fibronectin (R&D Systems), and treated daily with 10 g basic 
fibroblast growth factor 2 (FGF2 - R&D Systems). At DIV5, cells were passaged 
and plated out at 0.8-1.0 x106 cells per pre-coated plate and expanded as above 
for a further 3-4 days (expansion approx 300%). Cells were passaged again and 
plated out at 1.2-1.4 x106. After 1-2 days FGF2 was removed, cells washed once 
with medium and then resuspended in medium without FGF2 ± VA (or PB) (0.5 
mM each), and harvested after 4 days.  
 
Chromatin immunoprecipitation, mRNA studies and histone preparation 
Cortical gray matter (70-100mg, human; 30-50 mg, mouse) was stripped of 
adjacent white matter from the frozen blocks, then homogenized and digested 
with micrococcal nuclease for subsequent native chromatin immunoprecipitation 
(NChIP) followed by qPCR, exactly as described (Huang et al., 2006). For NChIP, 
anti-H3-trimethyl-lysine 4 (anti-H3K4me3) and anti-H3-trimethyl-lysine 27 
(anti-H3K27me3) antibodies (Upstate) were used, with rabbit serum as negative 
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control. Specificity of each antibody was monitored using dot blot assays with 
synthetic peptide (Supplemental Figure 2-2). Primers pairs chosen for quantitative 
analyses had to pass 2 filters (i) reliable amplification of specific 
(sequence-verified) product, (ii) primer slope with less than 25% variation from the 
expected value, 1.4427. Primer and genomic sequences are listed in 
Supplemental Table 2-2. To study Mll1 and RNA pol II occupancy, chromatin from 
extracted nuclei was prepared by crosslinking in 1% buffered formaldehyde for 10 
min, followed by sonication and immunoprecipitation with anti-Mll1 (Bethyl 
Laboratories) and anti-RNA pol II (Santa Cruz) antibodies. 
Total RNA was isolated and purified from brains by using RNeasy Lipid 
Tissue Mini Kit (Qiagen). Samples were treated with DNase I to avoid DNA 
contamination, then processed with TaqMan One-Step RT-PCR (Applied 
Biosystems) with suitable primers (Supplemental Table 2-2). From additional 
samples, biotinylated cRNA was hybridized to custom-made Oligo GEArray®  
Microarrays (Superarray BioScience) according to the manufacturer’s instructions 
and analyzed using the GEArray Expression Analysis Suite.  
Bulk histone preparations from cerebral cortex, Western blot analysis and 
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quantification of H3K4me2 and H3K4me3 levels were performed as described 
before (Kim et al., 2007). 
 
In situ hybridization and cell counting 
Brains were fixed in 4% phosphate-buffered paraformaldehyde (4 hours), and 
14 m sections were hybridized to DIG-11-UTP sense and antisense probes (15 
ng/25ml hybridization buffer/section) at 60oC overnight, then washed and digested 
with RNAse A and developed with the DIG Nucleic Acid detection kit (Roche). The 
proportion of Gad1 mRNA expressing cells, relative to the -actin-expressing cells 
cut through the level of the nucleus, was determined in 0.75x 1.25 mm counting 
frames positioned across the full thickness of the somatosensory cortex, using 
Bioquant software.  
 
Immunocytochemistry 
For immunocytochemistry, cultured cells were fixed with phosphate-buffered 
4% paraformaldehyde /0.2% glutaraldehyde, then permeabilized with 0.2% Triton 
X-100 and blocked with 10% goat serum, then incubated with primary antibody 
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(anti-Nestin, /-NeuN, -GABA (Chemicon and Sigma)) for 1 hr, then washed and 
incubated with Alexa 488- or 594-conjugated secondary antibodies (Molecular 
probes). For immunohistochemistry, brain sections were prepared as described 
above and then processed free-floating for Mll1- and Gad1 immunoreactivity in 
conjunction with Texas-Red and FITC-labeled secondary antibodies (VectorLabs) 
using standard protocols. 
 
Genotyping 
GAD1 SNP genotyping was performed using direct sequencing and also 
matrix-assisted laser desorption/inonization mass spectrometry (Sequenom), in 
conjunction with SpecroDesign software for PCR and MassEXTEND primers 
(Supplemental Table 2-2). 
 
Statistical analysis 
Methylation and transcript profiles across genomic loci, or age groups, or 
treatments in animals were evaluated by one-way analysis of variance (ANOVA) 
followed by post hoc Tukeys HSD or, in the case of non-normal distribution, by 
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Kruskal-Wallis statistic followed by Dunn’s test. Frequencies of cases that, in 
comparison to matched control, showed mRNA deficits in conjunction with histone 
methylation alterations were assessed with 2 x 3 contingency tables and 
Fisher-Freeman-Halton Exact test. Case/control (clinical samples) or 
mutant/wildtype (mice) comparisons with non-normal distribution were done by 
Wilcoxon signed-rank test, otherwise Student’s Paired t-test was applied. 
Postmortem confounds, including tissue pH, were assessed with Pearson’s 
correlation coefficient and did not show a significant effect on any of the chromatin 
markers of this study. Generalized effects of Mll1 gene dosage on H3K4 
methylation at GABAergic gene promoters were assessed in Mll1+/+ and +/- mice 
by the Binomial test.  Levels of H3K4me2 and H3K4me3 between wild-type and 
Mll1+/- samples were analyzed statistically as described (Kim et al., 2007). 
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Figure 2-1.  Chromatin remodeling at GABAergic gene loci during 
development and maturation of human prefrontal cortex (PFC). (A) GAD1 
mRNA levels in 55 subjects ranging in age from second trimester of pregnancy to 
old age (x-axis, log scale, B = birth, or “0.77 years”, P = puberty arbitrarily set at 
12.77 years), expressed for each sample as mean ± S.E.M from 3 independent 
qPCR amplicons/primer pairs after normalization to 18S rRNA (y-axis). Values of 
GAD1 mRNA from 55 subjects were weighted in each GAD1 mRNA primer and 
then averaged from 3 different GAD1 mRNA primers. Three GAD1 mRNA primers 
were used to make sure that the developmental trend of GAD1 mRNA is not due 
to the artificial effect of primer itself. Notice progressive increase during prenatal 
and postnatal development until puberty. (B)  Representative qPCR data from 
ChIP with anti-methyl-histone antibodies. Top, amplification curves of input (black), 
immunoprecipitates with anti-H3K27me3 (blue) and -H3K4me3 (red) antibodies 
and no antibody (as negative control, “no Ab”, green) as indicated. Bottom, SYBR 
Green-based melting curve and ethidium bromide-stained 3% agarose gel, 
showing a single peak in melting curve corresponding to the 122-bp product 
(GAD1, bp -440 to -319). Arrowheads = 100 and 200 bp DNA ladder. (C), 
ChIP-to-input ratios for 10 primer pairs positioned across 20 kb of GAD1 
sequence (x-axis) surrounding the transcription start site (TSS). CpG islands and 
exons I-III are indicated. N=8-12 samples/primer pair. Notice increased histone 
methylation in proximity of the TSS (Kruskal-Wallis, H3K4me3, p < 0.001 and 
H3K27me3 p < 0.05). (D, E) GAD1 mRNA and histone lysine 4 methylation, (D) 
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H3K4me3, and (E) H3K4me1, for GAD1, GAD2, SST and NPY promoters, the 
-Globin locus control region and Telomere-associated repeat 1, TAR1. Data are 
expressed as mean ± S.E.M for 3 age groups (fetal, 0-12 years old and > 12 years 
of age). Notice progressive and significant increase in GAD1 mRNA (black) and 
GAD1-H3K4me3 and H3K4me1 levels (red) from prenatal to postnatal/child and 
from postnatal/child to adolescent/adult stages, and similar profiles for GAD2, 
SST and NPY. * p < 0.01 compared to prenatal group, Dunn’s test. Micrococcal 
nuclease (MNase)-digested PFC chromatins were used as inputs. 
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Figure 2-2. Histone H3 methylation at GABAergic gene promoters in 
developing mouse cerebral cortex . (A), Histone methylation profile of adult 
mouse cerebral cortex at Gad1 locus (x-axis) Exons I-III and the three alternative 
promoters P1, P2 and P3 as indicated. N=5 samples/primer pair. Notice sharp rise 
in histone methylation in proximity of TSS (Kruskal-Wallis, H3K4me3, p = 0.001; 
H3K27me3, p < 0.05). (B), H3K4me3 at 5’ end of Gad1 (bp + 1048 to + 1145) (red) 
and Gad1 mRNA (black) levels at different stages of mouse cortical development 
(x-axis). Notice marked increase for both markers after P8 (One way ANOVA with 
Tukey HSD, * p < 0.05 – 0.005). (C), Representative images through the full 
thickness of somatosensory cortex from P8 (left) and P105 (right) sections 
hybridized with digoxigenin-labeled -actin or Gad1 antisense probes. The ratio of 
Gad1+: -actin+ cells across the vertical thickness of cortex was similar for both 
age groups (mean ± S.E.M. P8, 0.107 ± 0.003; P105, 0.127 ± 0.033. N = 3/group). 
Bar = 50 m. (D) Co-regulation of mRNA levels and histone H3K4-trimethylation 
during maturation from P8 to P105 cortex for Npy (top) and Sst (bottom) 
(two-sample t test, * p < 0.05).  
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Figure 2-3: Neuronal differentiation is accompanied by differential changes 
in H3K4 and H3K27 methylation at GABAergic gene loci. (A), Flowchart for 
expansion, passage (P) and treatment of cultured neural precursors from E14.5 
rat forebrain. (B) (a-c) digitized images showing Nestin and H3K4me3 
immunofluorescence and DAPI counterstain of undifferentiated cells, (d,e) 
GABAergic neurons (arrows) and (f,g) H3K4me3 and NeuN immunoreactivities in 
differentiated cultures. (C) Levels of Gad1, Npy and Sst1 mRNA, normalized to 
18S rRNA (y-axis) from 4 different culture conditions as indicated. Notice robust 
increase in Gad1 and Npy mRNA levels in differentiated cultures (-FGF2 ± PB or 
VA), in comparison to undifferentiated (+FGF2) cells. (D, E) Levels of (D) 
H3K4me3 and (E) H3K27me3 in nucleosomes positioned within 500 bp of rat 
Gad1, Npy and Sst transcription start sites (see Supplemental Table 2). Data 
expressed as mean ± S.E.M., N = 3 – 8 / treatment / assay. Notice robust increase 
in open (H3K4me3) but not repressive (H3K27me3) chromatin methylation at 
Gad1 and Npy promoters. * (C) = One way ANOVA with Tukey HSD (four groups 
were compared with each other), p < 0.05 – 0.005; (D, E) = two-tailed Student’s 
t-test, p < 0.05 – 0.005. 
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Figure 2-4. Histone methylation in GABAergic chromatin is regulated by 
Mll1. (A, a-c) Sections from P105 somatosensory cortex illustrating (a) distribution 
of Mll1 immunoreactive nuclei across cortical layers, and (b,c) expression in 
GABAergic neurons, (b) anti-Mll1 (red) /anti-Gad1 (green) immunoreactivity, (c) 
anti-Mll1/ digoxigenin-labeled Gad1 cRNA probe. Scale bars in (a), 50 m; (b) & 
(c), 25 m (B, a-b) Relative expression pattern (gray scale) of 30 histone 
methyltransferase enzymes and co-factors in (a) human fetal, child and adult PFC 
and in (b) mouse developing (E15.5) and adult (P105) cerebral cortex, as 
determined by custom-made oligonucleotide array. Notice high levels of MLL1/ 
Mll1 expression in comparison to other transcripts regulating H3K4 trimethylation. 
(C) Bar graphs summarizing data from chromatin immunoprecipitation assays, 
confirming Mll1 and RNA pol II occupancy at Gad1 locus in P8 and P105 cortex 
(N=5/assay). (D) Levels of (left) H3K4me3 and (right) H3K4me2 at Gad1/Npy/Sst 
promoters in cerebral cortex of adult Mll1 +/- and wildtype (wt) controls, after 
normalization to the B2M housekeeping gene. N = 11/genotype (H3K4me3), 5 
(H3K4me2). Notice decreased methylation in Mll1+/- animals (black columns) in 
6/6 comparisons (Binomial test, p = 0.03); for Gad1- and Npy-H3K4me3, p < 0.05, 
Wilcoxon signed-rank test (data are not normal distribution); Npy-H3K4me2, p < 
0.05, Student’s Paired t-test (data are normal distribution). (E) Levels of H3K4me2 
and H3K4me3 in bulk histone preparations form wild-type (light column) and 
Mll1+/- (dark column) brain. For each histone modification, the ratio of methylated 
histone versus total histone H3 was normalized against the respective wild-type 
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ratio expressed as 100% (N= 8 mice/genotype, data expressed as mean ± 
S.E.M.).  
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Figure 2-5. GAD1 histone methylation and gene expression changes in a 
subset of subjects with schizophrenia. (A) Levels of GAD1 mRNA, and open 
(H3K4me3) and repressive (H3K27me3) histone methylation in the 12 female (top) 
and 24 male (bottom) case-control pairs, after normalization to the B2M 
housekeeping gene. Notice that 9/12 female schizophrenia subjects have a 
decrease in GAD1 mRNA and 11/12 by a reduction in H3K4me3, in comparison to 
control. Notice no consistent changes in males. P-values shown for Wilcoxon 
signed-rank test. (B) GAD1 mRNA and H3K4me3 levels (y-axis, relative to 
matched control) show an inverse correlation with age-of-onset (x-axis; data were 
available from 27/36 schizophrenia subjects; male (female) = open black circle 
(open red circle) symbols). (C) Direct comparison of GAD1 H3K4me3 in 18 
control subjects between 15 and 80 years of age reveals progressive, age-related 
increases. Data in (B) and (C) shown after removal of extreme outlier (one/graph) 
(Stem-and-Leaf plot was done to determine the extreme outliners). (D) [Top] Map 
for 5’ portion of GAD1, including transcription start site (TSS), CpG islands, exons 
I-III and location of 5 SNPs associated with increased risk for psychiatric disease 
(Addington et al., 2005) (Lundorf et al., 2005; Straub et al., 2007a). [Bottom] 
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Effects of allelic load for SNP 2, 4 and 5 (x-axis) on frequency (y-axis) of 
schizophrenia cases that show decreased GAD1 mRNA levels together with 
decreased GAD1 H3K4me3 and increased GAD1 H3K27me3, in comparison to 
matched control. Notice that 35.5% (6 [4 male, 2 female] /18 [14 male, 4 female]) 
of schizophrenia subjects homozygous for the common allele (1/1) are affected by 
above event, but none with other genotypes (total N of schizophrenia subjects per 
genotype: 1/1 = 17 [SNP 2,4] or 18 [SNP 5]; 1 /2 = 12 [SNP 2,5] or 13 [SNP 4]; 2/2 
= 7 [SNP 2] or 6 [SNP 4,5]). 
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Figure 2-6. Histone methylation at Gad1/GAD1 locus is positively regulated 
by the antipsychotic, clozapine (A) Bar graphs for mouse cerebral cortex, 
showing H3K4me3 levels at Gad1 promoter. Left graph, wildtype mice after 3 
weeks of daily injections of 5mg/kg clozapine (Clz, black bar), 0.5 mg/kg 
haloperidol (Hal, shaded bar), or vehicle (white bar); right graph from Drd2-/-, 
Drd3-/- double null mutant and control mice. (B) Graphs (left) show cortical Mll1 
mRNA expression and (right) Mll1 occupancy at GAD1 promoter in cortex of mice 
after a single dose of clozapine (5 mg/kg) or vehicle. Data are expressed as mean 
± S.E.M. after normalization to housekeeping gene, 2-microglobulin (B2m); 
N=6-24/treatment or genotype (C) Bar graphs showing levels of (left) H3K4me3 
and (right) H3K27me3 at GAD1 locus in subjects treated with clozapine prior to 
death (black bars), relative to B2M housekeeping gene and compared to subjects 
treated with a typical antipsychotic (TA) (white bars). Notice significant, >2-fold 
increase in H3K4me3 in clozapine treated cohort (N=9), * = p < 0.05 (One way 
ANOVA with Tukey HSD (A, left), Two-sample t test (B, right) and Wilcoxon 
signed- rank test (B, left; C)). 
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Supplemental Figure 2-1. Profiles of histone methylation and gene 
expression in schizophrenics and their matched controls 
(A) Bar graphs showing levels of (left) GAD2 mRNA, (middle) GAD2-H3K4me3 
and (right) GAD2-H3K27me3 in 11(22) female (Male) schizophrenia subjects 
(black bars) and matched controls (white bars). Data normalized to the B2M 
housekeeping gene. (B, C) Levels of Mll1 mRNA (normalized to B2M) in (B) 
schizophrenia subjects vs. controls (same cohort shown in A) and (C) 
schizophrenia subjects treated with clozapine (Clz., black bars) or typical 
antipsychotic (TA, white bars). (D) Levels of GAD1 mRNA (normalized to B2M) in 
Clz. And TA-treated subjects. (C, D) N= 9/group. Data shown as mean +/- S.E.M., 
*p < 0.05 (Mann-Whitney Test) 
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Supplemental Figure 2-2. Specificity of the antibodies against mono-, di-, 
and tri-methyl histone H3 lysine 4 (H3K4) and tri-methyl histone H3 lysine 27 
(H3K27) 
Dot-blot assays were performed for testing the specificity of (A) mono-, di-, and 
tri-methyl H3K4 and (B) tri-methyl H3K27 antibodies when exposed to mono-, di-, 
and tri-methyl (A) H3K4 and (B) H3K27 peptides. Peptides and antibodies were 
used as the indicated concentrations and amounts. Spot peptides directly to the 
wetted PVDF membrane and allow it to dry. Membrane was wetted again with 
methanol and TBST (Tris-buffered saline containing 0.1% Twen-20), incubated 
with 5% dry milk in TBST, and then probed with primary and secondary 
antibodies. 
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Supplemental Table 2-1. Postmortem tissue (prefrontal cortex, Brodmann 
Area 10) 
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Supplemental Table 2-2. Primer sequences 
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CHAPTER IV: GAD1 MRNA EXPRESSION AND DNA METHYLATION IN 
PREFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA 
This work presented here in this chapter is reproduced from a study by 
Huang et al., published in PLoS ONE (Huang et al., 2007). 
This work was conducted under the direction of Dr. Schahram Akbarian, and it is 
with gratitude to him and the other authors that I reproduce these data for the 
purposes of this dissertation. My contributions to this work consisted of rat cell 
culture, immunofluorescence staining, native chromatin immunoprecipitation, 
mRNA extraction, RT-PCR, DNA sodium bisulfite conversion, subcloning, DNA 
sequencing and data analysis. Silvia Materna contributed by assisting in 
Methprimer design and tests, DNA sodium bisulfite conversion, subcloning, and 
DNA sequencing. Anouch Matevossian contributed by assisting in PCR and 
native chromatin immunoprecipitation. Catheryne Whittle contributed by assisting 
in establishing and maintaining rat differentiated neuron cultures. The manuscript 
was primarily prepared by Dr. Akbarian, while I contributed to the materials and 
methods, figures and legends, and provided feedback on other sections. 
 
114 
 
Abstract 
 Expression of glutamic acid decarboxylase 1 (GAD1), a key enzyme for 
GABA synthesis, is decreased in schizophrenic PFC. However, the molecular 
mechanisms contributing to the deficit of GAD1 are unclear. Alterations of DNA 
methylation as an epigenetic factor of gene regulation could play a role. However, 
it is difficult to test this hypothesis because no techniques are available to 
selectively extract DNA from GABAergic neurons efficiently in human postmortem 
brain.  
Here, we present an alternative approach that is based on 
immunoprecipitation of mononucleosomes with anti-methyl-histone (H3K4me3 
and H3K27me3) antibodies differentiating between sites of potential gene 
expression and silent genes. Methylation of CpG dinucleotides at the GAD1 
proximal promoter and intron 2 was measured from two separate chromatin 
fractions. In a case-control design, all 14 schizophrenia subjects had a decrease 
in prefrontal GAD1 mRNA levels.  
In controls, the methylation frequencies at CpG dinucleotdies, while overall 
higher in repressive as compared to open chromatin, did not exceed 5% at the 
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GAD1 proximal promoter and 30% within intron 2. Strikingly, schizophrenia 
subjects showed a significant 8-fold decrease of DNA methylation at the proximal 
promoter in repressive chromatin. The results indicate that chromatin remodeling 
mechanisms are associated with dysregulated GAD1 expression in 
schizophrenia. 
 
Introduction 
Deficits in GAD1 mRNA in schizophrenic PFC have been reported in different 
studies by using distinct human brain collections (reviewed in Akbarian and 
Huang, 2006). Recently, studies on prefrontal cortex of schizophrenia subjects 
identified several genes including SOX10 (Iwamoto et al., 2005), REELIN 
(Abdolmaleky et al., 2005; Grayson et al., 2005) and membrane-bound 
catechol-O-methyltransferase (MB-COMT) (Abdolmaleky et al., 2006), which are 
affected by altered DNA methylation in conjuction with changes in mRNA levels. 
Furthermore, increased Gad1 mRNA is accompanied by decreased Dnmt1 
expression and DNA methyltransferase activity after treatment with DNA 
methyltransferase inhibitors in NT-2 neuronal precursor cells (Kundakovic et al., 
116 
 
2007). Interestingly, levels of GAD1 mRNA are inversely correlated with levels of 
DNMT1 mRNA in the PFC of non-psychiatric subjects and psychiatric patients 
(Veldic et al., 2005). Moreover, DNMT1 mRNA is overexpressed in GABAergic 
neurons of schizophrenia subjects (Veldic et al., 2004).  
According to those pieces of evidence, a deficit of GAD1 mRNA in 
GABAergic neurons of schizophrenia subjects could be associated with increased 
DNA methylation at GAD1 promoter. However, it is difficult to test this hypothesis 
because no reproducible technique can be used for extracting genomic DNA 
specifically from GABAergic neurons in postmortem brains. Here, we show an 
alternative approach that is based on the rationale that active GAD1 expression is 
associated with the tri-methylation of histone H3-lysine 4 (H3K4me3), a chromatin 
mark that defines open chromatin at sites of active transcription (Hampsey and 
Reinberg, 2003; Sims et al., 2003). Therefore, we separated open and repressive 
chromatin from human prefrontal cortex with specific anti-methyl-histone 
antibodies, followed by measuring DNA methylation frequencies for each 
separate chromatin fraction. Furthermore, we focus on the potential role of DNA 
methylation at the GAD1 proximal promoter in schizophrenia subjects affected by 
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a deficit of GAD1 mRNA. 
 
Results 
Differential changes of H3K4me3 and H3K27me3 levels during neuronal 
differentiation 
To determine whether H3K4me3 at the Gad1 locus defines open chromatin 
and gene expression, and to examine potential effects of antipsychotic drug (APD) 
treatment on chromatin remodeling, we monitored open (H3K4me3) and 
repressive (H3K27me3) (Hampsey and Reinberg 2003; Sims et al. 2003) 
chromatin-associated histone methylation at the Gad1 locus in a neural 
differentiation assay for precursor cells from rat embryonic forebrain (Fig. 3-1A, 
see also Methods). In this assay, neuronal differentiation is induced by withdrawal 
of fibroblast growth factor 2 (FGF2) and addition of sodium valproate (VA) to the 
cell culture medium (Laeng et al., 2004). In comparison to undifferentiated 
precursor cells (“+FGF2” in Fig. 3-1A, B), neurons (“-FGF2/+VA” in Fig. 3-1A, B) 
showed, on average, a 168-fold fold increase in Gad1 mRNA levels by qRT-PCR, 
and this was associated with a 30-fold increase in H3K4me3 levels at the proximal 
Gad1 promoter (Fig. 3-1B). These changes were consistent in 3/3 experiments. 
In contrast to these dramatic increases in Gad1 mRNA and H3K4me3, levels of 
H3K27me3 – the repressive mark – showed a two-fold decrease upon neural 
differentiation (Fig. 3-1B). Furthermore, cultured neurons treated with the 
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antipsychotic, clozapine (“-FGF2 +VA +Clz” in Fig. 3-1B) for four days, did not 
show consistent changes in Gad1 mRNA, or Gad1-associated H3K4me3 and 
H3K27me3. From these experiments, we draw two conclusions: First, the tagging 
of Gad1 nucleosomes with H3K4me3 - a histone mark previously associated with 
open chromatin and actual or potential gene expression in non-neuronal tissues 
and cell lines (Straub et al., 2007a) – indeed reflects neuronal gene expression 
activity at that locus. Second, levels of open (H3K4me3) and repressive 
(H3K27me3) histone methylation at the Gad1 locus are not affected by treatment 
with the antipsychotic drug, clozapine in vitro for four days.  
 
Selective changes of DNA methylation at the GAD1 promoter in 
schizophrenic PFC 
 Next, we separated open (H3K4me3) and repressive (H3K27me3) chromatin 
from postmortem human prefrontal cortex prepared by micrococcal 
nuclease-based digestion prior to immunoprecipitation as previously described 
(Stadler et al., 2005; Huang et al., 2006). Then, we monitored GAD1 mCpG 
methylation in subclones of PCR products amplified from the immunoprecipitated 
DNA after bisulfite conversion. Altogether 70 primer pairs within 8kb of the GAD1 
proximal promoter and 5’ end sequences were tested; 67 primer pairs produced 
amplicons that lacked sequence specificity (data not shown). This was not 
surprising given that bisulfite-conversion reduces the genetic code to a 3 letter 
code in the absence of methylation. The design of suitable PCR primers is further 
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limited by the chromatin preparation technique that produces mononucleosomes 
with less than 148 bp of genomic DNA. The remaining 3 primer pairs 
(Supplemental Table 3-1) covered altogether 12 CpG’s positioned between 
-1120 to + 3400 bp from the GAD1 transcription start site (Fig. 3-2A). Methylation 
frequencies in repressive chromatin immunoprecipitated with anti-H3K27me3 
antibody were higher at 10/12 CpG dinucleotides, in comparison to open 
chromatin fractionated with anti-H3K4me3 antibody (Binomial test, p < 0.01) (Fig. 
3-2A upper panel).  Two CpG’s located within 200-250 bp upstream of the GAD1 
transcription start site remained unmethylated both in open and repressive 
chromatin, and DNA methylation levels were overall much lower at the promoter 
in comparison to intron 2 (Fig. 3-2A upper panel). Next, we monitored GAD1 CpG 
methylation levels in subjects diagnosed with schizophrenia and their matched 
controls. Levels of GAD1 DNA methylation in open chromatin (H3K4me3) were 
strikingly similar between schizophrenia subjects and controls, with extremely low 
levels at the promoter (<0.5%) (Fig. 3-2A lower panel, and Fig. 3-2B) and a 
higher methylation frequency (approximately 15%) within intron 2 (Fig. 3-2A lower 
panel, and Fig. 3-2C). Unexpectedly, however, GAD1 DNA methylation in 
repressive chromatin (H3K27me3) of schizophrenia subjects was significantly 
different from control subjects:  CpG methylation frequencies were on average 
3.5% in the control cohort but only 0.4% in the disease cohort (Fig. 3-2A lower 
panel, and Fig. 3-2B). This DNA methylation deficit in repressive GAD1 chromatin 
of schizophrenia subjects affected 5/8 GpG nucleotides (Fig. 3-2A lower panel) 
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and was significant (Wilcoxon Signed Ranks Test, p = 0.018). In contrast, the CpG 
methylation frequencies at intron 2 were very similar in cases and controls (Fig. 
3-2A, lower panel, and Fig. 3-2C) and were approximately 25% in both cohorts;  
these differences were not significant. Therefore, the deficit in prefrontal GAD1 
mRNA levels in this cohort of schizophrenia subjects (Fig. 3-2, see also Methods) 
is associated with a selective decrease in DNA methylation in repressive GAD1 
chromatin at the site of the proximal gene promoter.  
Among various GAD1 single nucleotide polymorphisms (SNP’s), two are 
positioned within 2 kb of the transcription start site (rs3749034 and rs2270335). 
These two SNP’s are included in a GAD1 haplotype that confers genetic risk for 
childhood-onset schizophrenia and accelerated loss of frontal gray matter 
(Addington et al., 2005). In order to rule out that GAD1 genotypes were different in 
the cases and controls of the present study, we determined allele frequencies for 
the two SNP’s. In both cohorts, allele frequencies were identical, which is 
expected given their close proximity (<1.5 kb) [Schizophrenia subjects, allele (1/1) 
57%, (1/2) 29%, (2/2) 14%; controls (1/1) 79%, (1/2) 14%, (2/2) 7%]. Notably, the 
case and control cohorts showed no significant difference in the number of 
subjects bi-allelic for the common allele (1/1), which defines the at risk haplotype 
(Addington et al., 2005) (Pearson chi-square X2 = 0.47, df =1, p = 0.5). 
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Furthermore, overall allele frequencies were not significantly different between the 
two cohorts (Fisher’s Exact Test). 
 
Discussion 
To the best of our knowledge, we are the first to assess DNA methylation in 
human brain for open and repressive chromatin separately. In the open chromatin 
fractions of the present study, which were defined by trimethylation of histone H3 
lysine 4 (H3K4me3) (Hampsey and Reinberg, 2003; Sims et al., 2003), GAD1 
DNA methylation was overall much lower, in comparison to repressive chromatin 
that is defined by trimethylation of histone H3 lysine 27, (H3K27me3) (Sims et al., 
2003). However, even in repressive/silenced chromatin, only a fraction of GAD1 
CpG dinucleotides (<30% for intron 2, and <5% at the promoter) are subjected to 
DNA methylation in human prefrontal cortex. Unexpectedly, DNA methylation at 
the GAD1 proximal promoter in repressive chromatin showed significant 
decreases in schizophrenia subjects affected by the deficit of GAD1 mRNA. 
Our profiling data for DNA methylation across the proximal promoter and 
intron 2 of the GAD1 gene in human brain are consistent with the idea that gene 
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promoters are more resistant to DNA methylation (Caiafa and Zampieri, 2005). 
Moreover, it has been shown that regulation of gene activity is coordinated at both 
the histone and DNA levels (Fuks et al., 2003; Wang et al., 2005; Zhang et al., 
2005). Therefore, it would not be so surprising that higher frequencies of 
methylation at CpG dinucleotides occurred in repressive chromatin, which is 
defined by the H3K27me3 mark here.  
Given that DNA methylation around the proximal promoter typically 
contributes to transcriptional repression, it was expected that schizophrenia 
subjects would show increased GAD1 DNA methylation. Instead, we observed a 
significant decrease in CpG methylation at the GAD1 proximal promoter in the 
repressive chromatin fraction of schizophrenia subjects. Further studies are 
necessary in order to determine if these changes are related to altered GAD1 
gene transcription. Notably, the schizophrenia subjects of the present study had 
lower GAD1 mRNA levels in comparison to the matched controls (see Methods 
and Fig. 3-3). One plausible explanation would be that in the affected cases, there 
is an increased proportion of GAD1 nucleosomes tagged with the repressive mark, 
H3K27me3, but without concomitant methylation of the genomic DNA (Fig. 3-4). 
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Therefore, repressive chromatin-associated histone methylation at the GAD1 
locus in schizophrenia appears to be, at least in part, independent of CpG 
methylation. The present study faces an important limitation because reliable 
PCR amplification across multiple subjects was achieved only for a dozen GAD1 
CpG’s, and we cannot exclude an important role for any of the approximately 400 
additional CpG sites that surround the first 5 kb of GAD1 transcription start site. 
Therefore, our findings have to be viewed as preliminary. Furthermore, it will be of 
interest to determine in future studies whether the observed DNA methylation 
deficits in H3K27me3-tagged GAD1 nucleosomes of schizophrenia subjects are 
specific for that gene or part of a more widespread DNA methylation defect of the 
disorder. 
 
Materials and methods 
Human brains 
All procedures were approved by the Institutional Review Board of the 
University of Massachusetts Medical School. Demographics, postmortem 
confounds and RNA data for the case and control cohorts are presented in Table 
3-1. Each pair consisted of a subject with schizophrenia and a control matched for 
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age, gender and autolysis time. The prefrontal cortex of the 14 schizophrenia 
subjects included in the present study showed, in comparison to the matched 
control, a decrease in GAD1 mRNA levels, as determined by qRT-PCR with 3 
different sets of PCR primers and normalization to the housekeeping gene 
transcript, 2-microglobulin (B2M) (Table 3-1 and Fig. 3-3). In addition, for 3 of 
the matched pairs, the decrease in GAD1 mRNA levels in the schizophrenia 
subjects had been observed in a previous study that used in situ hybridization 
histochemistry (Akbarian et al., 1995). The remaining 11 matched pairs were not 
included in that earlier study, but were collected by the same brain bank and 
subjected to the same diagnostic criteria and inclusion/exclusion criteria as 
previously described (Akbarian et al., 1995).  
 
DNA methylation 
For DNA methylation studies, nucleosomes first were extracted from 
prefrontal cortex gray matter and then immunoprecipitated with two 
anti-methyl-histone specific antibodies [anti-histone H3-tri-methyl-lysine 4 
(H3K4me3) and anti-H3-tri-methyl-lysine 27 (H3K27me3)] to separate open 
chromatin at sites of actual or potential transcription from repressive and silenced 
chromatin, exactly as described (Stadler et al., 2005; Huang et al., 2006). Salmon 
sperm as a blocking agent was omitted and instead all samples were first 
pre-cleared by 30 min agarose pre-incubation prior to the immunoprecipitation 
procedure. DNA purified from immunoprecipitates was subjected to sodium 
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bisulfite conversion followed by purification and elution, using the EZ DNA 
methylation kit (Zymo Research), according to the manufacturer’s instructions. 
Methprimer software (http://www.urogene.org/methprimer) was used to design 
primer pairs for GAD1 sequences. Three primer pairs (Supplemental Table 3-1) 
altogether covering 12 CpG’s positioned between -1120 to + 3400 bp from the 
GAD1 transcription start site, were choosen to profile DNA methylation patterns in 
control brains (Fig. 3-2A upper panel). PCR amplicons were gel-purified, 
subcloned into pCR4-TOPO vector, purified in 96 well plates (Qiagen Turbo 
Miniprep) and for each subject, 12 clones from each immunoprecipitate were 
analyzed by sequencing. For each subject, DNA methylation levels were 
expressed as % methylated CpG’s separately for each primer pair. Differences 
between schizophrenia and control subjects were evaluated by two sample t-test, 
or in the case of non-normal distribution, by Mann-Whitney test separately for 
open and repressive chromatin fractions. Furthermore, for each case and control, 
genotyping for selected GAD1 single nucleotide polymorphism was performed 
using matrix-assisted laser desorption/inonization mass spectrometry 
(Sequenom), in conjunction with SpectroDesign software for PCR and 
MassEXTEND primers (Gabriel and Ziaugra, 2004). 
 
Cell cultures 
Neural precursor cells were prepared from forebrain of E14.5 SASCO SD rat 
embryos (Charles River). Live cells were plated out at 1.2-1.4x106 cells per 
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100-mm poly-l-lysine coated dishes pre-coated with 15 g/ml poly-l-ornithine 
(Sigma) and 1 g/ml fibronectin (R&D Systems), and treated daily with 10 g 
basic fibroblast growth factor 2 (FGF2 - R&D Systems). At DIV5, cells were 
passaged and plated out at 0.8-1.0 x106 cells per pre-coated plate and expanded 
as above for a further 3-4 days (expansion approx 300%). Cells were passaged 
again and plated out at 1.2-1.4 x106, and after 1-2 days FGF2 was removed, cells 
washed once with medium and then resuspended in DMEM/M2/F12 medium 
(Invitrogen) without FGF2 but with 0.5 mM sodium valproate and with or without 1 
M clozapine, and harvested after 4 days. 
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Figure 3-1: Histone methylation changes at the Gad1 promoter in a neuronal 
differentiation assay. (A) (a-j) Digitized images showing (a-c) undifferentiated 
neural precursors grown in FGF2 (fibroblast growth factor 2)-containing medium 
and (d-j) neurons differentiated in medium without FGF2 but with VA (sodium 
valproate); notice that precursors (a) , but not neurons (d) are defined by nestin 
immunoreactivity, while both type of cells express robust  H3K4me3 
immunoreactivity (c,f); (g,i) representative examples of neuronal marker (g, NeuN 
and i, GABA) immunoreactivity. All images taken at 20x10 (200X) magnification. 
(B) (top) levels of Gad1 mRNA (y-axis, log scale), expressed relative to 18S rRNA 
and (middle and bottom) ChIP-to-input ratios (y-axis, log scale) of site-specific 
histone methylation (H3K4me3 and H3K27me3) in the nucleosomes positioned 
-374 to -273 bp of rat Gad1 promoter. Data expressed as mean +/- S.E.M., with 
N=3 for each of the three different culture conditions. Notice robust increase of 
Gad1 mRNA and H3K4me3 levels in differentiated cultures (-FGF2+VA), in 
comparison to undifferentiated cells (+FGF2); that treatment with the 
antipsychotic clozapine did not affect histone methylation or Gad1 gene 
expression in cultured neurons. VA = Valproic acid, Clz = Clozapine. * = P< 0.01 
(One way ANOVA with Tukey HSD, -FGF2+VA (or –FGF2+VA+Clz)-treated cells 
were compared with +FGF2-treated cells). When comparisons were performed in 
Gad1 H3K4me3 or H3K27me3 levels, none of them reached level of significance. 
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Figure 3-2: GAD1 DNA methylation in prefrontal cortex of subjects with 
schizophrenia and comparison subjects. (A) (upper panel) GAD1 DNA 
methylation profile in open (H4K4me3) and repressive (H3K27me3) chromatin. 
Percentage of methylated GAD1 CpG residues in DNA from immunoprecipitates 
(y-axis, ●, anti-H3K4me3; △, anti-H3K27me3) for 12 CpG’s (shown in red) 
positioned between bp - 1150 to + 3400 relative to the GAD1 transcription start 
site. Primer pairs marked by arrows (N = 3-15 control subjects/CpG dinucleotide); 
(lower panel) averaged levels of methylation for each of the 12 GAD1 CpG 
residues (see Fig. 3-2, upper panel) in schizophrenia subjects (S) , expressed 
relative to control, C (S/C, y-axis). Notice decreased methylation of 5/8 CpG’s at 
the GAD1 promoter of schizophrenia subjects (B,C) Averaged frequency of DNA 
methylation across the 8 CpG’s at the GAD1 (B) proximal promoter (see Fig. 3-2A, 
upper panel) and (C) intron 2 in schizophrenia and matched control subjects, as 
indicated (N=12 clones/primer pair/case or control). Data shown for open (“K4” = 
H3Kme3) and repressive (“K27” = H3K27me3) chromatin separately. Notice 
significant deficit in repressive chromatin-associated DNA methylation at the 
GAD1 promoter in schizophrenia subjects (P = 0.018, Wilcoxon Signed Ranks 
Test). 
 
 
 
 
131 
 
 
 
 
 
132 
 
Figure 3-3: GAD1 mRNA levels in schizophrenia subjects and matched 
controls. Levels of GAD1 mRNA in 14 controls (C) matched to 14 schizophrenia 
(S) subjects, as determined by qRT-PCR separately for 3 different primer pairs 
spanning different exons. Data shown after log-transformation and normalization 
with the housekeeping gene transcript, 2-microglobulin.   
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Figure 3-4: DNA methylation changes at the GAD1 locus in schizophrenia. 
(Top) schematic presentation of GAD1 CpG dinucleotides (open labels, 
unmethylated and filled labels, methylated) in normal prefrontal cortex, showing 
higher levels of DNA methylation in repressive (“K27” = H3K27me3) as opposed 
to open (“K4” = H3K4me3) chromatin. Notice overall low DNA methylation at the 
proximal GAD1 promoter. (Bottom) In schizophrenia, GAD1 promoter DNA 
methylation in repressive chromatin (“K27”) is further decreased from control 
values. A hypothetical but plausible mechanism would be the conversion from 
open chromatin to repressive chromatin that becomes tagged with the histone 
mark, H3K27me3, but without additional DNA methylation. 
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Table 3-1. Postmortem collections 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
Supplemental Table 3-1. Primer for bisulfite-converted GAD1 DNA (sense 
strand) 
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CHAPTER V: GENERAL DISCUSSION 
In this dissertation, I investigated the potential roles of histone modifications 
and DNA methylation in the etiology of schizophrenia. We show that methylation of 
histone H3 lysine 4, a chromatin mark associated with active transcription, 
increased progressively at GAD1 and other GABAergic gene promoters (GAD2, 
NPY and SST) in human prefrontal cortex (PFC) from prenatal to peripubertal 
ages and throughout adulthood. Alterations in schizophrenia including decreased 
GAD1 expression and H3K4-trimethylation, predominantly in females, and in 
conjunction with increased H3K27-trimethylation, are associated with a risk 
haplotype at the 5’ end of GAD1. Heterozygosity for a truncated lacZ knock-in 
allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed 
in GABAergic and other cortical neurons, resulted in decreased H3K4 methylation 
at GABAergic gene promoters. In contrast, Gad1 H3K4-trimethylation and Mll1 
occupancy at Gad1 promoter were increased in the cerebral cortices of mice after 
treatment with the atypical antipsychotic, clozapine. These effects were not 
mimicked by haloperidol or genetic ablation of dopamine D2 and D3 receptors, 
suggesting that blockage of D2-like signaling is not sufficient for clozapine-induced 
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histone methylation.  As to DNA methylation, schizophrenia subjects with a deficit 
in GAD1 mRNA also showed decreased methylation of CpG dinucleotides at the 
GAD1 promoter in repressive chromatin.  
 Here, I would like to point out fertile research areas for epigenetic 
mechanisms in CNS neurons.  
After the first histone demethylase (HDM), lysine-specific demethylase 1 
(LSD1), was discovered in 2004 (Shi et al., 2004), 7 other HDMs were discovered 
within 2 years (Shi and Whetstine, 2007). These findings on HDMs revolutionized 
the previous idea that histone methylation was irreversible. Indeed, histone 
demethylation by HDMs might play a role in the deficit of GAD1 H3K4me3 levels 
found in female schizophrenics. The deficit of GAD1 H3K4me3 could be due, at 
least in part, to an imbalance in expression or coordination of HDMs and histone 
methyltransferases (HMTs). This possibility needs to be further investigated. 
Moreover, the interactions among different histone modifications need to be 
addressed by additional studies. For example, it has been known that methylation 
at histone H3 arginine 2 (H3R2) can exclude the methylation at histone H3 lysine 
4 (H3K4) as well as the recruitment of Mll1 (Guccione et al., 2007).  
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  Histone modification marks and their corresponding gene activities have 
already been defined in different organisms (Peterson and Laniel, 2004), but the 
molecular mechanisms linking these marks and their corresponding gene 
activities are still unknown. Therefore, the molecules recognizing and interacting 
with specific histone marks need to be further determined. Another important 
issue to be addressed is the downstream mechanisms that are activated after 
modulators bind to their corresponding histone marks. I believe that the results of 
such studies could clarify why mRNA levels of GABAergic genes in Mll1 mutant 
mice did not change even though H3K4me3 levels significantly decreased in a 
subset of GABAergic genes.  
 Another interesting question to be addressed is whether Mll1 mutant mice 
show schizophrenia-like phenotypes. Behavioral experiments with Mll1 mutant 
mice have been limited due to embryonic lethality in the homozygous mutant 
strain and inactivity and sickness in the heterozygous mutant strain (Yu et al., 
1995). Fortunately, conditional Mll1 knockout mice have recently been generated 
(Jude et al., 2007). These mice could be engineered to delete Mll1 in specific 
brain regions by mating with transgenic mice expressing Cre in different brain 
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regions. These mice could be behaviorally tested for potential schizophrenia-like 
phenotypes. If these behavioral tests showed that the conditional Mll1 knockout 
mice had defects in working memory, which is one core symptom of schizophrenia, 
then an even more meaningful question to address would be whether the PFC of 
these mutant mice show dysfunction of synaptic plasticity. Taken together, the 
results of such experiments would definitely move us to another level of 
understanding of the roles epigenetic factors play in brain functions. 
 My results show that clozapine increases levels of Gad1 H3K4me3, which 
was not affected by blockade of D2-like signaling such as by haloperidol treatment 
or D2/D3 deletion. These results may be confirmed by treating D2/D3-knockout 
mice with clozapine. Clozapine can block a wide range of receptors including 
dopaminergic (D4), adrenergic, cholinergic, histaminergic and serotonergic 
receptors. The receptor(s) involved in changing Gad1 chromatin structure need to 
be explored. This exploration might shed light on why clozapine is more effective 
than other antipsychotic drugs in treating negative symptoms of schizophrenia. 
 My results suggest that female schizophrenics have severe deficits in the 
levels of GAD1 mRNA and GAD1 H3K4me3, whereas male schizophrenics do not. 
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Furthermore, in our cohort schizophrenic patients, females had later age of onset 
than males, in agreement with previous findings (Hafner et al., 1998; Lieberman 
et al., 2001). Here, I hypothesize that these differences in age of onset and deficit 
of GAD1 chromatin structure could be mediated by estrogen. For example, 
estradiol-17-beta, the female sex hormone, has neuroprotective properties and 
could be involved in ameliorating schizophrenia symptoms (Rao and Kolsch, 
2003). Nearly 30% of individuals affected by mental illness perceive menopause 
to worsen symptoms of mental illness (Sajatovic et al., 2003). Interestingly, 
estradiol-17-beta can activate estrogen receptors and then this activated complex 
can recruit menin, one integral component of Mll1, to trimethylate at histone H3 
lysine 4 (Dreijerink et al., 2006). 
 The results of my dissertation work may lead to a better understanding of 
how environmental inputs influence the pathogenesis of schizophrenia through 
epigenetic factors, e.g., histone modifications and DNA methylation. These results 
may provide information to improve the treatment of schizophrenia. 
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